腫瘍病理鑑別診断アトラス　悪性軟部腫瘍　改訂・改題　第2版

出版社： 文光堂
著者：
発行日： 2021-04-14
分野： 臨床医学：基礎  >  臨床病理学
ISBN： 9784830622564
シリーズ： 腫瘍病理鑑別診断アトラス
電子書籍版： 2021-04-14 （改訂・改題第2版第1刷）
書籍・雑誌
≪全国送料無料でお届け≫
取寄せ目安：約3営業日

19,800 円(税込)

購入する
電子書籍
章別単位での購入はできません
ブラウザ、アプリ閲覧

19,800 円(税込)

購入する

商品紹介

腫瘍病理鑑別診断アトラスシリーズ「悪性軟部腫瘍」，待望の改訂・改題第2版．軟部腫瘍はその種類が極めて多いが，本書では「悪性軟部腫瘍」に焦点を絞り，頻度の高い重要な組織型を中心に解説した．鑑別診断において重要となる良性や中間群についても取り上げている．WHO分類第5版（2020）の内容や，遺伝子学的知見などの最新の知見を交じえながら，精選した病理写真とともに診断のポイントを解説．悪性軟部腫瘍病理診断のスタンダードを示す1冊であり，病理医はもちろん，悪性軟部腫瘍の診断・治療に携わるすべての医師必携の書．

目次

  • 第1部　検鏡前の確認事項
    　I．軟部腫瘍の組織型分類：WHO分類について
    　　1．2020年軟部腫瘍WHO分類（第5版）の特徴
    　　2．細胞分化に基づいた大分類の詳細
    　II．病理標本の取扱い方
    　　1．検体採取と固定までの取扱い
    　　2．固定標本の肉眼観察と切り出し
    　　3．染色，遺伝子検索

    第2部　組織型と診断の実際
    　I．脂肪性腫瘍
    　　1．異型紡錘形細胞/多形脂肪腫様腫瘍
    　　2．脂肪肉腫
    　II．線維芽細胞および筋線維芽細胞腫瘍
    　　1．デスモイド線維腫症
    　　2．隆起性皮膚線維肉腫
    　　3．孤立性線維性腫瘍
    　　4．炎症性筋線維芽細胞腫瘍
    　　5．粘液線維肉腫
    　　6．低悪性線維粘液性肉腫/硬化性類上皮線維肉腫
    　III．脈管性腫瘍
    　　1．偽筋原性血管内皮腫
    　　2．類上皮血管内皮腫
    　　3．血管肉腫
    　IV．平滑筋性腫瘍
    　　1．EBV関連平滑筋腫瘍
    　　2．平滑筋肉腫
    　V．骨格筋性腫瘍
    　　1．横紋筋肉腫
    　VI．末梢神経性腫瘍
    　　1．悪性末梢神経鞘腫瘍
    　VII．分化不明腫瘍
    　　1．筋肉内粘液腫
    　　2．類血管腫線維性組織球腫
    　　3．筋上皮腫/筋上皮癌/混合腫瘍
    　　4．高リン尿性間葉系腫瘍
    　　5．NTRK 遺伝子再構成紡錘形細胞腫瘍
    　　6．滑膜肉腫
    　　7．類上皮肉腫
    　　8．胞巣状軟部肉腫
    　　9．軟部明細胞肉腫
    　　10．骨外性粘液型軟骨肉腫
    　　11．線維形成性小円形細胞腫瘍
    　　12．ラブドイド腫瘍
    　　13．血管周囲類上皮細胞腫瘍
    　　14．未分化肉腫
    　VIII．骨軟部発生未分化小円形細胞肉腫
    　　1．EWSR 1-non ETS 融合遺伝子陽性肉腫
    　　2．CIC 遺伝子再構成肉腫
    　　3．BCOR 遺伝子異常肉腫

    第3部　鑑別ポイント
    　I．紡錘形細胞肉腫
    　　1．有用と思われる前提知識
    　　2．代表的疾患の組織学的・免疫組織化学的特徴
    　　3．常に鑑別候補に含めておくべき疾患
    　　4．診断に難渋する場合
    　　COLUMN　紡錘形腫瘍細胞の形態による分化方向の推定と主な配列パターン
    　II．小円形細胞腫瘍
    　　1．Ewing肉腫
    　　2．Ewing様肉腫
    　　3．線維形成性小円形細胞腫瘍
    　　4．胎児型横紋筋肉腫
    　　5．胞巣型横紋筋肉腫
    　III．多形肉腫
    　　1．高悪性度多形肉腫という概念
    　　2．多形型平滑筋肉腫
    　　3．多形型横紋筋肉腫
    　　4．多形型脂肪肉腫
    　　5．未分化多形肉腫
    　　6．高悪性度多形肉腫のゲノム
    　　7．高悪性度多形肉腫の鑑別診断の実際
    　IV．粘液性腫瘍
    　　1．軟部腫瘍における粘液腫状変化について
    　　2．表在性（主に真皮内）の病変
    　　3．主に皮下の粘液性腫瘍
    　　4．深在性粘液性腫瘍
    　V．上皮様腫瘍
    　　1．類上皮血管肉腫
    　　2．二相型滑膜肉腫
    　　3．ラブドイド腫瘍
    　　4．類上皮肉腫
    　VI．筋線維芽細胞増殖性病変
    　　1．結節性筋膜炎
    　　2．反応性および良性増殖性病変の鑑別診断
    　　3．主な鑑別すべき病変
    　　4．いわゆる炎症性偽腫瘍について
    　VII．良性末梢神経腫瘍
    　　1．Schwann細胞腫
    　　2．神経線維腫
    　　3．神経周膜腫
    　　4．顆粒細胞腫
    　　5．皮膚神経鞘粘液腫
    　　6．孤在性限局神経腫
    　　7．混成性神経鞘腫瘍

    第4部　臨床との連携
    　I．病理診断報告書の記載
    　　1．病理診断報告書の構成
    　　2．病理診断
    　　3．病理診断所見（コメント）
    　　4．FNCLCC Grading System
    　II．軟部肉腫の進行期と治療方針・予後
    　　1．軟部肉腫の病期分類の概要
    　　2．AJCC/UICC staging system（8th edition）
    　　3．Surgical Staging System（SSS）
    　　4．Memorial Sloan Kettering Cancer Center（MSKCC）の分類
    　　5．軟部肉腫の進行期と予後
    　　6．軟部肉腫の進行期別治療法
    　　7．軟部肉腫の進行期分類と治療の実際
    　　8．まとめ
    　III．軟部肉腫の薬物療法
    　　1．抗悪性腫瘍薬に高い感受性をもつと考えられている肉腫
    　　2．抗悪性腫瘍薬に相対的に低い感受性をもつと考えられている肉腫（その他の肉腫）
    　　3．開発中の分子標的治療薬について
    　IV．軟部肉腫の画像診断
    　　1．単純X線写真
    　　2．超音波検査
    　　3．CT
    　　4．MRI
    　　5．核医学検査（FDG-PET）
    　　6．病理診断と画像の相関―MRIを中心に―
    　　7．病理診断と画像検査の相補関係
    　V．軟部腫瘍の遺伝子診断と新たな遺伝学的解析方法
    　　1．軟部腫瘍診療における遺伝子診断の意義
    　　2．軟部腫瘍における遺伝子診断の対象
    　　3．遺伝子診断の実際
    　　4．遺伝子診断結果の取り扱いと病理学的手法を用いた評価
    　　5．今後の展望
    　VI．軟部肉腫の組織学的治療効果判定と切除縁評価
    　　1．組織学的治療効果判定
    　　2．切除縁評価

この書籍の参考文献

参考文献のリンクは、リンク先の都合等により正しく表示されない場合がありますので、あらかじめご了承下さい。

本参考文献は電子書籍掲載内容を元にしております。

第1部 検鏡前の確認事項

P.9 掲載の参考文献
1) WHO Classification of Tumours Editorial Board : WHO Classification of Tumours 5th Edition Soft Tissue and Bone Tumours. IARC Press, Lyon, 2020
 
2) Fletcher CDM, Unni KK, Mertens F (eds) : World Health Organization Classification of Tumours. Pathology and Genetics of Tumours of Soft Tissue and Bone. IARC Press, Lyon, 2002
 
3) Fletcher CDM, Bridge JA, Hongendoorn PCW et al (eds) : WHO Classification of Tumours of Soft Tissue and Bone. IARC Press, Lyon, 2013
 
4) 日本整形外科学会 骨・軟部腫瘍委員会編 : 整形外科・病理 悪性軟部腫瘍取扱い規約, 第3版, 金原出版, 2002
 
P.13 掲載の参考文献
1) 日本病理学会編 : ゲノム研究用・診療用病理組織検体取扱い規程, 羊土社, 2019, p6
 
2) 日本病理学会編 : ゲノム研究用・診療用病理組織検体取扱い規程, 羊土社, 2019, p4
 
3) Hitchman E, Hodgkinson C, Roberts D et al : Effect of prolonged formalin fixation on immunohistochemical staining for the proliferation marker Ki67. Histopathology 59 : 1261-1263, 2011
PubMed
4) Dempster WT : Rates of penetration of fixing fluids. Am J Anat 107 : 59-72, 1960
PubMed
5) Sunami K, Ichikawa H, Kubo T et al : Feasibility and utility of a panel testing for 114 cancer-associated genes in a clinical setting : A hospital-based study. Cancer Sci 110 : 1480-1490, 2019
 

第2部 組織型と診断の実際

P.19 掲載の参考文献
1) Creytens D, Marino-Enriquez A : Atypical spindle cell/pleomorphic lipomatous tumor. WHO classification of tumours. Soft tissue and bone tumours, IARC Press, Lyon, 2020, pp34-35
 
2) Dei Tos AP, Mentzel T, Newman PL et al : Spindle cell liposarcoma, a hitherto unrecognized variant of liposarcoma. Analysis of six cases. Am J Surg Pathol 18 : 913-921, 1994
PubMed
3) Mentzel T, Palmedo G, Kuhnen C : Well-differentiated spindle cell liposarcoma ('atypical spindle cell lipomatous tumor') does not belong to the spectrum of atypical lipomatous tumor but has a close relationship to spindle cell lipoma : clinicopathologic, immunohistochemical, and molecular analysis of six cases. Mod Pathol 23 : 729-736, 2010
PubMed
4) Marino-Enriquez A, Nascimento AF, Ligon AH et al : Atypical Spindle Cell Lipomatous Tumor : Clinicopathologic Characterization of 232 Cases Demonstrating a Morphologic Spectrum. Am J Surg Pathol 41 : 234-244, 2017
PubMed
5) Creytens D, van Gorp J, Savola S et al : Atypical spindle cell lipoma : a clinicopathologic, immunohistochemical, and molecular study emphasizing its relationship to classical spindle cell lipoma. Virchows Arch 465 : 97-108, 2014
PubMed
6) Creytens D, Mentzel T, Ferdinande L et al : "Atypical" Pleomorphic Lipomatous Tumor : A Clinicopathologic, Immunohistochemical and Molecular Study of 21 Cases, Emphasizing its Relationship to Atypical Spindle Cell Lipomatous Tumor and Suggesting a Morphologic Spectrum (Atypical Spindle Cell/Pleomorphic Lipomatous Tumor). Am J Surg Pathol 41 : 1443-1455, 2017
PubMed
7) Ko JS, Daniels B, Emanuel PO et al : Spindle Cell Lipomas in Women : A Report of 53 Cases. Am J Surg Pathol 41 : 1267-1274, 2017
PubMed
P.31 掲載の参考文献
1) 山口洋, 長谷川 匡 : 軟部肉腫の病理診断と治療. 癌と化学療法 31 : 1340-1345, 2004
Medical*Online
2) Sbaraglia M, Dei Tos AP, Pedeutour F et al : Atypical lipomatous tumor/well-differentiated liposarcoma. in Antonescu CR, Blay JV, Bovee JVMG et al (eds) : "World Health Organization Classification of Tumours・5th edition. Soft Tissue and Bone Tumours", IARC Press, Lyon, 2020, pp36-38
 
3) Coindre JM, Pedeutour F, Aurias A : Well-differentiated and dedifferentiated liposarcomas. Virchows Arch 456 : 167-179, 2010
PubMed
4) Binh MBN, Sastre-Garau X, Guillou L et al : MDM2 and CDK4 immunostainings are useful adjuncts in diagnosing well-differentiated and dedifferentiated liposarcoma subtypes : a comparative analysis of 559 soft tissue neoplasms with genetic data. Am J Surg Pathol 29 : 1340-1347, 2005
 
5) Creytens D : What's new in adipocytic neoplasia? Virchows Arch 476 : 29-39, 2020
 
6) Creytens D, Mario-Enriquez : Atypical spindle cell/pleomorphic lipomatous tumor. in Antonescu CR, Blay JV, Bovee JVMG et al (eds) : "World Health Organization Classification of Tumours・5th edition. Soft Tissue and Bone Tumours", IARC Press, Lyon, 2020, pp34-35
 
7) Sir vent N, Coindre JM, Maire G et al : Detection of MDM2-CDK4 amplification by fluorescence in situ hybridization in 200 paraffin-embedded tumor samples : utility in diagnosing adipocytic lesions and comparison with immunohistochemistry and real-time PCR. Am J Surg Pathol 31 : 1476-1489, 2007
 
8) Weaver J, Downs-Kelly E, Goldblum JR et al : Fluorescence in situ hybridization for MDM2 gene amplification as a diagnostic tool in lipomatous neoplasms. Mod Pathol 21 : 943-949, 2008
PubMed
9) Coindre JM, Mariani O, Chibon F et al : Most malignant fibrous histiocytomas developed in the retroperitoneum are dedifferentiated liposarcomas : a review of 25 cases initially diagnosed as malignant fibrous histiocytoma. Mod Pathol 16 : 256-262, 2003
PubMed
10) Chung L, Lau SK, Jiang Z et al : Overlapping features between dedifferentiated liposarcoma and undifferentiated high-grade pleomorphic sarcoma. Am J Surg Pathol 33 : 1594-1600, 2009
 
11) Hasegawa T, Seki K, Hasegawa F et al : Dedifferentiated liposarcoma of retroperitoneum and mesentery : varied growth patterns and histological grades-a clinicopathologic study of 32 cases. Hum Pathol 31 : 717-727, 2000
PubMed
12) Mussi C, Collini P, Miceli R et al : The prognostic impact of dedifferentiation in retroperitoneal liposarcoma : a series of surgically treated patients at a single institution. Cancer 113 : 1657-1665, 2008
 
13) Evans HL : Atypical lipomatous tumor, its variants, and its combined forms : a study of 61 cases, with a minimum follow-up of 10 years. Am J Surg Pathol 31 : 1-14, 2007
PubMed
14) Boland JM, Weiss SW, Oliveira AM et al : Liposarcomas with mixed well-differentiated and pleomorphic features : a clinicopathologic study of 12 cases. Am J Surg Pathol 34 : 837-843, 2010
PubMed
15) Marino-Enriquez A, Fletcher CDM, Dal Cin P et al : Dedifferentiated liposarcoma with "homologous" lipoblastic (pleomorphic liposarcoma-like) differentiation : clinicopathologic and molecular analysis of a series suggesting revised diagnostic criteria. Am J Surg Pathol 34 : 1122-1131, 2010
PubMed
16) de Vreeze RSA, de Jong D, Tielen IHG et al : Primary retroperitoneal myxoid/round cell liposarcoma is a nonexisting disease : an immunohistochemical and molecular biological analysis. Mod Pathol 22 : 223-231, 2009
 
17) Kilpatrick SE, Doyon J, Choong PF et al : The clinicopathologic spectrum of myxoid and round cell liposarcoma. A study of 95 cases. Cancer 77 : 1450-1458, 1996
PubMed
18) Tateishi U, Hasegawa T, Beppu Y et al : Prognostic significance of grading (MIB-1 system) in patients with myxoid liposarcoma. J Clin Pathol 56 : 579-582, 2003
PubMed
19) Smith TA, Easley KA, Goldblum JR : Myxoid/round cell liposarcoma of the extremities. A clinicopathologic study of 29 cases with particular attention to extent of round cell liposarcoma. Am J Surg Pathol 20 : 171-180, 1996
PubMed
20) Antonescu CR, Tschernyavsky SJ, Decuseara R et al : Prognostic impact of P53 status, TLS-CHOP fusion transcript structure, and histological grade in myxoid liposarcoma : a molecular and clinicopathologic study of 82 cases. Clin Cancer Res 7 : 3977-3987, 2001
PubMed
21) Tateishi U, Hasegawa T, Beppu Y et al : Prognostic significance of MRI findings in patients with myxoid-round cell liposarcoma. AJR Am J Roentgenol 182 : 725-731, 2004
PubMed
22) Antonescu CR, Elahi A, Humphrey M et al : Specificity of TLS-CHOP rearrangement for classic myxoid/round cell liposarcoma : absence in predominantly myxoid well-differentiated liposarcomas. J Mol Diagn 2 : 132-138, 2000
PubMed
23) Alaggio R, Creytens D : Myxoid pleomorphic liposarcoma. in Antonescu CR, Blay JV, Bovee JVMG et al (eds) : "World Health Organization Classification of Tumours・5th edition. Soft Tissue and Bone Tumours", IARC Press, Lyon, 2020, pp47-48
 
24) Alaggio R, Coffin CM, Weiss SW et al : Liposarcomas in young patients. a study of 82 cases occurring in patients younger than 22 years of age. Am J Surg Pathol 33 : 645-658, 2009
PubMed
P.35 掲載の参考文献
1) Hizawa K, Iida M, Mibu R et al : Desmoid tumors in familial adenomatous polyposis/Gardner's syndrome. J Clin Gastroenterol 25 : 334-337, 1997
 
2) Fritchie KJ, Crago AM, van de Rijn M : Desmoid fibromatosis. in WHO Classification of Tumours Editorial Board (ed) : "WHO Classification of Tumours, 5th ed, Soft tissue and Bone Tumours", IRAC Press, Lyon, 2020, pp93-95
 
3) Miettinen M, Fetsch JF, Antonescu CR et al : AFIP Atlas of Tumor Pathology, Tumors of the Soft Tissues, 4th series, fascicle 20, AFIP, Washington DC, 2014, pp92-98
 
4) Zreik RT, Fritchie KJ : Morphologic Spectrum of Desmoid-Type Fibromatosis. Am J Clin Pathol 145 : 332-340, 2016
PubMed
5) Amary MF, Pauwels P, Meulemans E et al : Detection of beta-catenin mutations in paraffin-embedded sporadic desmoid-type fibromatosis by mutation-specific restriction enzyme digestion (MSRED) : an ancillary diagnostic tool. Am J Surg Pathol 31 : 1299-1309, 2007
PubMed
6) Gurbuz AK, Giardiello FM, Petersen GM et al : Desmoid tumours in familial adenomatous polyposis. Gut 35 : 377-381, 1994
PubMed
7) Bhattacharya B, Dilworth HP, Iacobuzio-Donahue C et al : Nuclear beta-catenin expression distinguishes deep fibromatosis from other benign and malignant fibroblastic and myofibroblastic lesions. Am J Surg Pathol 29 : 653-659, 2005
PubMed
8) Goldblum JR, Folpe AL, Weiss SW : Enzinger & Weiss's Soft Tissue Tumors (7th ed), Elsevier, Philadelphia, 2020, pp306-318
 
9) Yamashita K, Haga H, Mikami Y et al : Degree of IgG4+ plasma cell infiltration in retroperitoneal fibrosis with or without multifocal fibrosclerosis. Histopathology 52 : 404-409, 2008
PubMed
10) Khosroshahi A, Carruthers MN, Stone JH et al : Rethinking Ormond's disease : "idiopathic" retroperitoneal fibrosis in the era of IgG4-related disease. Medicine (Baltimore) 92 : 82-91, 2013
 
P.41 掲載の参考文献
1) Fletcher CDM, Unni KK, Mertens F (eds) : Pathology and genetics. Tumours of soft tissue and bone (4th ed), IARC Press, Lyon, 2013
 
2) Weiss SW, Goldblum JR : Enzinger and Weiss's Soft Tissue Tumors (5th ed), Mosby, St. Louis, 2008
 
3) Lopez LV, Yatsenko SA, Burgess M et al : Dermatofibrosarcoma protuberans with fibrosarcomatous transformation : our experience, molecular evaluation of selected cases, and short literature review. Int J Dermatol 58 : 1246-1252, 2019
PubMed
4) Kuzel P, Mahmood MN, Metelitsa AI et al : A clinicopathologic review of a case series of dermatofibrosarcoma protuberans with fibrosarcomatous differentiation. J Cutan Med Surg 19 : 28-34, 2015
 
5) Zhang Z, Chen H, Chen M et al : Application of COL1A1-PDGFB fusion gene detection by fluorescence in situ hybridization in biopsy tissue of dermatofibrosarcoma protuberans. J Dermatol 44 : 798-802, 2017
 
6) Navarrete-Dechent C, Mori S, Barker CA et al : Imatinib Treatment for Locally Advanced or Metastatic Dermatofibrosarcoma Protuberans : A Systematic Review. JAMA Dermatol 155 : 361-369, 2019
PubMed
7) Llombart B, Serra C, Requena C et al : Guidelines for diagnosis and treatment of cutaneous sarcomas : Dermatofibrosarcoma protuberans. Actas Dermosifiliogr 109 : 868-877, 2018
PubMed
8) Pedeutour F, Lacour JP, Perrin C et al : Another case of t (17 ; 22) (q22 ; q13) in an infantile dermatofibrosarcoma protuberans. Cancer Genet Cytogenet 89 : 175-176, 1996
 
9) Bednar B : Storiform neurofibromas of the skin, pigmented and nonpigmented. Cancer 10 : 368-376, 1957
PubMed
10) Reimann JD, Fletcher CD : Myxoid dermatofibrosarcoma protuberans : a rare variant analyzed in a series of 23 cases. Am J Surg Pathol 31 : 1371-1377, 2007
 
11) Calonje E, Fletcher CD : Myoid differentiation in dermatofibrosarcoma protuberans and its fibrosarcomatous variant : clinicopathologic analysis of 5 cases. J Cutan Pathol 23 : 30-36, 1996
 
12) Kutzner H, Mentzel T, Palmedo G et al : Plaque-like CD34-positive dermal fibroma ("medallion-like dermal dendrocyte hamartoma") : clinicopathologic, immunohistochemical, and molecular analysis of 5 cases emphasizing its distinction from superficial, plaque-like dermatofibrosarcoma protuberans. Am J Surg Pathol 34 : 190-201, 2010
PubMed
13) Reddy KK, Hanke CW, Tierney EP : Malignancy arising within cutaneous tattoos : case of dermatofibrosarcoma protuberans and review of literature. J Drugs Dermatol 10 : 837-842, 2011
PubMed
P.47 掲載の参考文献
1) Demicco EG, Fritchie KJ, Han A : Solitary fibrous tumor, World Health Organization Classification of Tumours, Soft Tissue and Bone Tumours, IARC Press, L yon, 2020, pp104-108
 
2) 山田裕一, 小田義直 : 孤立性線維性腫瘍と血管周皮腫, 軟部腫瘍 : 変化する疾患概念. 病理と臨床 34 : 584-589, 2016
 
3) Briselli M, Mark EJ, Dickersin GR : Solitary fibrous tumors of the pleura : eight new cases and review of 360 cases in the literature. Cancer 47 : 2678-2689, 1981
PubMed
4) Robinson DR, Wu YM, Kalyana-Sundaram S et al : Identification of recurrent NAB2-STAT6 gene fusions in solitary fibrous tumor by integrative sequencing. Nat Genet 45 : 180-185, 2013
PubMed
5) Chmielecki J, Crago AM, Rosenberg M et al : Whole-exome sequencing identifies a recurrent NAB2-STAT6 fusion in solitary fibrous tumors. Nat Genet 45 : 131-132, 2013
PubMed
6) Demicco EG, Park MS, Araujo DM et al : Solitary fibrous tumor : a clinicopathological study of 110 cases and proposed risk assessment model. Mod Pathol 25 : 1298-1306, 2012
PubMed
7) Demicco EG, Wagner MJ, Maki RG et al : Risk assessment in solitary fibrous tumors : validation and refinement of a risk stratification model. Mod Pathol 30 : 1433-1442, 2017
PubMed
8) Collini P, Negri T, Barisella M et al : High-grade sarcomatous overgrowth in solitary fibrous tumors : a clinicopathologic study of 10 cases. Am J Surg Pathol 36 : 1202-1215, 2012
PubMed
9) Thway K, Hayes A, Ieremia E et al : Heterologous osteosarcomatous and rhabdomyosarcomatous elements in dedifferentiated solitary fibrous tumor : further support for the concept of dedifferentiation in solitary fibrous tumor. Ann Diagn Pathol 17 : 457-463, 2013
PubMed
10) Kurisaki-Arakawa A, Akaike K, Hara K et al : A case of dedifferentiated solitary fibrous tumor in the pelvis with TP53 mutation. Virchows Arch 465 : 615-621, 2014
PubMed
11) Schweizer L, Koelsche C, Sahm F et al : Meningeal hemangiopericytoma and solitary fibrous tumors carry the NAB2-STAT6 fusion and can be diagnosed by nuclear expression of STAT6 protein. Acta Neuropathol 125 : 651-658, 2013
PubMed
12) Doyle LA, Vivero M, Fletcher CD et al : Nuclear expression of STAT6 distinguishes solitary fibrous tumor from histologic mimics. Mod Pathol 27 : 390-395, 2014
PubMed
13) Yoshida A, Tsuta K, Ohno M et al : STAT6 immunohistochemistry is helpful in the diagnosis of solitary fibrous tumors. Am J Surg Pathol 38 : 552-559, 2014
PubMed
14) Barthelmes S, Geddert H, Boltze C et al : Solitary fibrous tumors/hemangiopericytomas with different variants of the NAB2-STAT6 gene fusion are characterized by specific histomorphology and distinct clinicopathological features. Am J Pathol 184 : 1209-1218, 2014
 
15) Yamada Y, Kohashi K, Kinoshita I et al : Clinicopathological review of solitary fibrous tumors : dedifferentiation is a major cause of patient death. Virchows Arch 475 : 467-477, 2019
PubMed
16) Kohashi K, Oda Y, Yamamoto H et al : Reduced expression of SMARCB1/INI1 protein in synovial sarcoma. Mod Pathol 23 : 981-990, 2010
PubMed
17) Doyle LA, Vivero M, Fletcher CD et al : Nuclear expression of STAT6 distinguishes solitary fibrous tumor from histologic mimics. Mod Pathol 27 : 390-395, 2014
PubMed
18) Yamada Y, Yamamoto H, Kohashi K et al : Histological spectrum of angiofibroma of soft tissue : histological and genetic analysis of 13 cases. Histopathology 69 : 459-469, 2016
PubMed
19) Bahrami A, Weiss SW, Montgomery E et al : RT-PCR analysis for FGF23 using paraffin sections in the diagnosis of phosphaturic mesenchymal tumors with and without known tumor induced osteomalacia. Am J Surg Pathol 33 : 1348-1354, 2009
 
20) Yamada Y, Kinoshita I, Kenichi K et al : Histopathological and genetic review of phosphaturic mesenchymal tumours, mixed connective tissue variant. Histopathology 72 : 460-471, 2018
PubMed
21) Lee JC, Su SY, Changou CA et al : Characterization of FN1-FGFR1 and novel FN1-FGF1 fusion genes in a large series of phosphaturic mesenchymal tumors. Mod Pathol 29 : 1335-1346, 2016
 
P.52 掲載の参考文献
1) Yamamoto H : Inflammatory myofibroblastic tumour. in Antonescu CR, Bridge JA, Cunha IW et al (eds) : WHO Classification of Tumours. Soft Tissue and Bone Tumours, 5th ed, IARC Press, Lyon, 2020, pp109-111
 
2) 山元英崇, 小田義直 : 炎症性筋線維芽細胞性腫瘍とその周辺疾患. 病理と臨床 30 : 258-264, 2012
Medical*Online
3) Yamamoto H, Yamaguchi H, Aishima S et al : Inflammatory myofibroblastic tumor versus IgG4-related sclerosing disease and inflammatory pseudotumor : a comparative clinicopathologic study. Am J Surg Pathol 33 : 1330-1340, 2009
PubMed
4) Marino-Enriquez A, Wang WL, Roy A et al : Epithelioid inflammatory myofibroblastic sarcoma : An aggressive intraabdominal variant of inflammatory myofibroblastic tumor with nuclear membrane or perinuclear ALK. Am J Surg Pathol 35 : 135-144, 2011
PubMed
5) Lee JC, Li CF, Huang HY et al : ALK oncoproteins in atypical inflammatory myofibroblastic tumours : novel RRBP1-ALK fusions in epithelioid inflammatory myofibroblastic sarcoma. J Pathol 241 : 316-323, 2017
PubMed
6) Takeuchi K, Soda M, Togashi Y et al : Pulmonary inflammatory myofibroblastic tumor expressing a novel fusion, PPFIBP1-ALK : reappraisal of anti-ALK immunohistochemistry as a tool for novel ALK fusion identification. Clin Cancer Res 17 : 3341-3348, 2011
PubMed
7) Lovly CM, Gupta A, Lipson D et al : Inflammatory myofibroblastic tumors harbor multiple potentially actionable kinase fusions. Cancer Discov 4 : 889-895, 2014
PubMed
8) Hornick JL, Sholl LM, Dal Cin P et al : Expression of ROS1 predicts ROS1 gene rearrangement in inflammatory myofibroblastic tumors. Mod Pathol 28 : 732-739, 2015
PubMed
9) Antonescu CR, Suurmeijer AJ, Zhang L et al : Molecular characterization of inflammatory myofibroblastic tumors with frequent ALK and ROS1 gene fusions and rare novel RET rearrangement. Am J Surg Pathol 39 : 957-967, 2015
PubMed
10) Yamamoto H, Yoshida A, Taguchi K et al : ALK, ROS1 and NTRK3 gene rearrangements in inflammatory myofibroblastic tumours. Histopathology 69 : 72-83, 2016
PubMed
11) Yamamoto H, Nozaki Y, Kohashi K et al : Diagnostic utility of pan-Trk immunohistochemistry for inflammatory myofibroblastic tumours. Histopathology 76 : 774-778, 2020
PubMed
12) Mason EF, Fletcher CD, Sholl LM : 'Inflammatory myofibroblastic tumour' -like dedifferentiation of anaplastic lymphoma kinase-rearranged lung adenocarcinoma. Histopathology 69 : 510-515, 2016
PubMed
13) Lucas DR, Shukla A, Thomas DG et al : Dedifferentiated liposarcoma with inflammatory myofibroblastic tumor-like features. Am J Surg Pathol 34 : 844-851, 2010
PubMed
14) Davis JL, Lockwood CM, Stohr B et al : Expanding the spectrum of pediatric NTRK-rearranged mesenchymal tumors. Am J Surg Pathol 43 : 435-445, 2019
PubMed
P.58 掲載の参考文献
1) WHO Classification of Tumours Editorial Board : Soft tissue and bone tumours. WHO classification of tumours (5th ed, vol 3), IARC Press, Lyon, 2020
 
2) Fletcher CDM : Tumors of soft tissue. in Fletcher CDM (ed) : "Diagnostic Histopathology of Tumors (5th ed)", Elsevier, Philadelphia, 2020
 
3) Goldblum JR, Folpe AL, Weiss SW : "Enzinger & Weiss's Soft tissue tumors (7th ed)", Elsevier, Philadelphia, 2020
 
4) Angervall L, Kindblom LG, Merck C : Myxofibrosarcoma : a study of 30 cases. Acta Pathol Microbiol Scand A 85A : 127-140, 1977
PubMed
5) Weiss SW, Enzinger FM : Myxoid variant of malignant fibrous histiocytoma. Cancer 39 : 1672-1685, 1977
 
6) Fletcher CDM : Pleomorphic malignant fibrous histiocytoma : fact or fiction? A critical reappraisal based on 159 tumors diagnosed as pleomorphic sarcoma. Am J Surg Pathol 16 : 213-228, 1992
PubMed
7) Mentzel T, Calonje E, Wedden C et al : Myxofibrosarcoma : clinicopathologic analysis of 75 cases with emphasis on the low-grade variant. Am J Surg Pathol 20 : 391-405, 1996
 
8) Waters B, Panicek DM, Lefkowitz RA et al : Low-grade myxofibrosarcoma : CT and MRI patterns in recurrent disease. AJR Am J Roentgenol 188 : W193-198, 2007
PubMed
9) Kaya M, Wada T, Nagoya S et al : MRI and histological evaluation of the infiltrative growth pattern of myxofibrosarcoma. Skeletal Radiol 37 : 1085-1090, 2008
PubMed
10) Nascimento AF, Bertoni F, Fletcher CDM : Epithelioid variant of myxofibrosarcoma : expanding the clinicomorphologic spectrum of myxofibrosarcoma in a series of 17 cases. Am J Surg Pathol 31 : 99-105, 2007
 
11) Evans HL : Low-grade fibromyxoid sarcoma : a report of two metastasizing neoplasms having a deceptively benign appearance. Am J Clin Pathol 88 : 615-619, 1987
PubMed
12) Huang HY, Brennan MF, Singer S et al : Distant metastasis in retroperitoneal dedifferentiated liposarcoma is rare and rapidly fatal : a clinicopathological study with emphasis on the low-grade myxofibrosarcoma-like pattern as an early sign of dedifferentiation. Mod Pathol 18 : 976-984, 2005
 
13) Coindre JM, Mariani O, Chibon F et al : Most malignant fibrous histiocytomas developed in the retroperitoneum are dedifferentiated liposarcomas : a review of 25 cases initially diagnosed as malignant fibrous histiocytoma. Mod Pathol 16 : 256-262, 2003
PubMed
14) Willems SM, Debiec-Rychter M, Szuhai K et al : Local recurrence of myxofibrosarcoma is associated with increase in tumour grade and cytogenetic aberrations, suggesting a multistep tumour progression model. Mod Pathol 19 : 407-416, 2006
 
15) Heitzer E, Sunitsch S, Gilg MM et al : Expanded molecular profiling of myxofibrosarcoma reveals potentially actionable targets. Mod Pathol 30 : 1698-1709, 2017
PubMed
16) Ogura K, Hosoda F, Arai Y et al : Integrated genetic and epigenetic analysis of myxofibrosarcoma. Nat Commun 9 : 2765, 2018
PubMed
P.64 掲載の参考文献
1) Antonescu CR, Rosenblum MK, Pereira P et al : Sclerosing epithelioid fibrosarcoma : a study of 16 cases and confirmation of a clinicopathologically distinct tumor. Am J Surg Pathol 25 : 699-709, 2001
PubMed
2) Evans HL : Low-grade fibromyxoid sarcoma. A report of two metastasizing neoplasms having a deceptively benign appearance. Am J Clin Pathol 88 : 615-619, 1987
PubMed
3) Evans HL : Low-grade fibromyxoid sarcoma. A report of 12 cases. Am J Surg Pathol 17 : 595-600, 1993
PubMed
4) Lane KL, Shannon RJ, Weiss SW : Hyalinizing spindle cell tumor with giant rosettes : a distinctive tumor closely resembling low-grade fibromyxoid sarcoma. Am J Surg Pathol 21 : 1481-1488, 1997
PubMed
5) Folpe AL, Lane KL, Paull G et al : Low-grade fibromyxoid sarcoma and hyalinizing spindle cell tumor with giant rosettes : a clinicopathologic study of 73 cases supporting their identity and assessing the impact of high-grade areas. Am J Surg Pathol 24 : 1353-1360, 2000
PubMed
6) Evans HL : Low-grade fibromyxoid sarcoma : a clinicopathologic study of 33 cases with long-term follow-up. Am J Surg Pathol 35 : 1450-1462, 2011
PubMed
7) Goldblum JR, Folpe AL, Weiss SW : Enzinger and Weiss's Soft Tissue Tumors (7th ed), Elsevier, Philadelphia, 2019, pp336-365
 
8) Doyle LA, Moller E, Dal Cin P et al : MUC4 is a highly sensitive and specific marker for low-grade fibromyxoid sarcoma. Am J Surg Pathol 35 : 733-741, 2011
PubMed
9) Guillou L, Benhattar J, Gengler C et al : Translocation-positive low-grade fibromyxoid sarcoma : clinicopathologic and molecular analysis of a series expanding the morphologic spectrum and suggesting potential relationship to sclerosing epithelioid fibrosarcoma : a study from the French Sarcoma Group. Am J Surg Pathol 31 : 1387-1402, 2007
 
10) Creytens D, Ferdinande L, Van Dorpe J : A Sclerosing Perineurioma With Collagen Rosette Formation : Benign Mimic of Low-Grade Fibromyxoid Sarcoma. Int J Surg Pathol 26 : 145-147, 2018
 
11) Moller E, Hornick JL, Magnusson L et al : FUS-CREB3L2/L1-positive sarcomas show a specific gene expression profile with upregulation of CD24 and FOXL1. Clin Cancer Res 17 : 2646-2656, 2011
PubMed
12) Arbajian E, Puls F, Antonescu CR et al : In-depth Genetic Analysis of Sclerosing Epithelioid Fibrosarcoma Reveals Recurrent Genomic Alterations and Potential Treatment Targets. Clin Cancer Res 23 : 7426-7434, 2017
PubMed
13) Meis-Kindblom JM, Kindblom LG, Enzinger FM : Sclerosing epithelioid fibrosarcoma. A variant of fibrosarcoma simulating carcinoma. Am J Surg Pathol 19 : 979-993, 1995
 
14) Arbajian E, Puls F, Magnusson L et al : Recurrent EWSR1-CREB3L1 gene fusions in sclerosing epithelioid fibrosarcoma. Am J Surg Pathol 38 : 801-808, 2014
PubMed
15) Prieto-Granada C, Zhang L, Chen HW et al : A genetic dichotomy between pure sclerosing epithelioid fibrosarcoma (SEF) and hybrid SEF/low-grade fibromyxoid sarcoma : a pathologic and molecular study of 18 cases. Genes Chromosomes Cancer 54 : 28-38, 2015
 
16) Puls F, Agaimy A, Flucke U et al : Recurrent Fusions Between YAP1 and KMT2A in Morphologically Distinct Neoplasms Within the Spectrum of Low-grade Fibromyxoid Sarcoma and Sclerosing Epithelioid Fibrosarcoma. Am J Surg Pathol 44 : 594-606, 2020
PubMed
17) Doyle LA, Wang WL, Dal Cin P et al : MUC4 is a sensitive and extremely useful marker for sclerosing epithelioid fibrosarcoma : association with FUS gene rearrangement. Am J Surg Pathol 36 : 1444-1451, 2012
PubMed
18) Sambri A, Righi A, Tuzzato G et al : Low-grade fibromyxoid sarcoma of the extremities : a clinicopathologic study of 24 cases and review of the literature. Pol J Pathol 69 : 219-225, 2018
PubMed
P.69 掲載の参考文献
1) Billings SD, Folpe AL, Weiss SW : Epithelioid sarcoma-like hemangioendothelioma. Am J Surg Pathol 27 : 48-57, 2003
PubMed
2) Hornick JL, Fletcher CD : Pseudomyogenic hemangioendothelioma : a distinctive, often multicentric tumor with indolent behavior. Am J Surg Pathol 35 : 190-201, 2011
PubMed
3) Righi A, Gambarotti M, Picci P et al : Primary pseudomyogenic haemangioendothelioma of bone : report of two cases. Skeletal Radiol 44 : 727-731, 2015
PubMed
4) Inyang A, Mertens F, Puls F et al : Primary Pseudomyogenic Hemangioendothelioma of Bone. Am J Surg Pathol 40 : 587-598, 2016
PubMed
5) Joseph J, Wang WL, Patnana M et al : Cytotoxic and targeted therapy for treatment of pseudomyogenic hemangioendothelioma. Clin Sarcoma Res 5 : 22, 2015
PubMed
6) Ozeki M, Nozawa A, Kanda K et al : Everolimus for Treatment of Pseudomyogenic Hemangioendothelioma. J Pediatr Hematol Oncol 39 : e328-e331, 2017
PubMed
7) Danforth OM, Tamulonis K, Vavra K et al : Effective Use of Sirolimus and Zoledronic Acid for Multiosteotic Pseudomyogenic Hemangioendothelioma of the Bone in a Child : Case Report and Review of Literature. J Pediatr Hematol Oncol 41 : 382-387, 2019
 
8) Gabor KM, Sapi Z, Tiszlavicz LG et al : Sirolimus therapy in the treatment of pseudomyogenic hemangioendothelioma. Pediatr Blood Cancer 65 : 2018
PubMed
9) van IJzendoorn DGP, Sleijfer S, Gelderblom H et al : Telatinib Is an Effective Targeted Therapy for Pseudomyogenic Hemangioendothelioma. Clin Cancer Res 24 : 2678-2687, 2018
PubMed
10) Sugita S, Hirano H, Kikuchi N et al : Diagnostic utility of FOSB immunohistochemistry in pseudomyogenic hemangioendothelioma and its histological mimics. Diagn Pathol 11 : 75, 2016
PubMed
11) Hung YP, Fletcher CD, Hornick JL : FOSB is a Useful Diagnostic Marker for Pseudomyogenic Hemangioendothelioma. Am J Surg Pathol 41 : 596-606, 2017
PubMed
12) Walther C, Tayebwa J, Lilljebjorn H et al : A novel SERPINE1-FOSB fusion gene results in transcriptional upregulation of FOSB in pseudomyogenic haemangioendothelioma. J Pathol 232 : 534-540, 2014
PubMed
13) Agaram NP, Zhang L, Cotzia P et al : Expanding the Spectrum of Genetic Alterations in Pseudomyogenic Hemangioendothelioma With Recurrent Novel ACTB-FOSB Gene Fusions. Am J Surg Pathol 42 : 1653-1661, 2018
PubMed
14) Zhu G, Benayed R, Ho C et al : Diagnosis of known sarcoma fusions and novel fusion partners by targeted RNA sequencing with identification of a recurrent ACTB-FOSB fusion in pseudomyogenic hemangioendothelioma. Mod Pathol 32 : 609-620, 2019
PubMed
P.75 掲載の参考文献
1) Rubin BP, Deyrup AT, Doyle LA : Epithelioid haemangioendothelioma. in WHO Classification of Tumours Editorial Board (ed) : "WHO Classification of Tumours, 5th ed, Soft tissue and Bone Tumours", IRAC Press, Lyon, 2020, pp172-175
 
2) Enzinger FM, Weiss SW : Soft Tissue Tumors, 3rd ed, CV Mosby, St. Louis, 1995, pp641-677
 
3) Weiss SW, Enzinger FM : Epithelioid hemangioendothelioma : a vascular tumor often mistaken for a carcinoma. Cancer 50 : 970-981, 1982
PubMed
4) Weiss SW, Ishak KG, Dail DH et al : Epithelioid hemangioendothelioma and related lesions. Semin Diagn Pathol 3 : 259-287, 1986
PubMed
5) Mentzel T, Beham A, Calonje E et al : Epithelioid hemangioendothelioma of skin and soft tissues : clinicopathologic and immunohistochemical study of 30 cases. Am J Surg Pathol 21 : 363-374, 1997
PubMed
6) Weiss SW, Bridge JA : Epithelioid haemangioendothelioma. in Fletcher CDM, Unni KK, Mertens F (eds) : World Health Organization Classification of Tumours. Pathology and genetics of tumours of soft tissue and bone, IRAC Press, Lyon, 2002, pp173-175
 
7) Fukunaga M : Expression of D2-40 in lymphatic endothelium of normal tissues and in vascular tumours. Histopathology 46 : 396-402, 2005
PubMed
8) Errani C, Sung YS, Zhang L et al : Monoclonality of multiple epithelioid hemangioendothelioma of the liver by analysis of WWTR1-CAMTA1 breakpoints. Cancer Genet 205 : 12-17, 2012
PubMed
9) Antonescu CR, Le Loarer F, Mosquera JM et al : Novel YAP1-TFE3 fusion defines a distinct subset of epithelioid hemangioendothelioma. Genes Chromosomes Cancer 52 : 775-784, 2013
PubMed
10) Mendlick MR, Nelson M, Pickering D et al : Translocation t(1 ; 3) (p36.3 ; q25) is a nonrandom aberration in epithelioid hemangioendothelioma. Am J Surg Pathol 25 : 684-687, 2001
 
11) Miettinen M, Fetsch JF : Distribution of keratins in normal endothelial cells and a spectrum of vascular tumors : implications in tumor diagnosis. Hum Pathol 31 : 1062-1067, 2000
 
12) Errani C, Zhang L, Sung YS et al : A novel WWTR1-CAMTA1 gene fusion is a consistent abnormality in epithelioid hemangioendothelioma of different anatomic sites. Genes Chromosomes Cancer 50 : 644-653, 2011
PubMed
13) Tanas MR, Sboner A, Oliveira AM et al : Identification of a disease-defining gene fusion in epithelioid hemangioendothelioma. Sci Transl Med 3 : 98ra82, 2011
PubMed
14) Doyle LA, Fletcher CD, Hornick JL : Nuclear expression of CAMTA1 distinguishes epithelioid hemangioendothelioma from histologic mimics. Am J Surg Pathol 40 : 94-102, 2016
PubMed
15) Fukunaga M, Suzuki K, Saegusa N et al : Composite hemangioendothelioma : report of 5 cases including one with associated Maffucci syndrome. Am J Surg Pathol 31 : 1567-1572, 2007
PubMed
16) Nayler SJ, Rubin BP, Calonje E et al : Composite hemangioendothelioma : a complex, low-grade vascular lesion mimicking angiosarcoma. Am J Surg Pathol 24 : 352-361, 2000
PubMed
17) Fletcher CD, Beham A, Bekir S et al : Epithelioid angiosarcoma of deep soft tissue : distinctive tumor readily mistaken for an epithelial neoplasm. Am J Surg Pathol 15 : 915-924, 1991
PubMed
18) Billings SD, Folpe AL, Weiss SW : Epithelioid sarcoma-like hemangioendothelioma. Am J Surg Pathol 27 : 48-57, 2003
PubMed
19) Hornick JL, Fletcher CDM : Pseudomyogenic hemangioendothelioma : a distinctive, often multicentric tumor with indolent behavior. Am J Surg Pathol 35 : 190-201, 2011
 
20) Deyrup AT, Tighiouart M, Montag AG et al : Epithelioid hemangioendothelioma of soft tissue : a proposal for risk stratification based on 49 cases. Am J Surg Pathol 32 : 924-927, 2008
 
P.81 掲載の参考文献
1) Goldblum JR, Folpe AL, Weiss SW : Enzinger & Weiss's Soft Tissue Tumors (7th ed), Elsevier, Philadelphia, 2020, pp785-799
 
2) 日本整形外科学会 骨・軟部腫瘍委員会編 : 整形外科・病理悪性軟部腫瘍取扱い規約, 第3版, 金原出版, 2002
 
3) Mankey CC, McHugh JB, Thomas DG et al : Can lymphangiosarcoma be resurrected? A clinicopathological and immunohistochemical study of lymphatic differentiation in 49 angiosarcomas. Histopathology 56 : 364-371, 2010
PubMed
4) Martinez AP, Zapata M, North PE et al : Lymphatic-type "angiosarcoma" with prominent lymphocytic infiltrate. Am J Surg Pathol 44 : 271-279, 2020
PubMed
5) Holden CA, Spittle MF, Jones EW : Angiosarcoma of the face and scalp, prognosis and treatment. Cancer 59 : 1046-1057, 1987
PubMed
6) Mark RJ, Poen JC, Tran LM et al : Angiosarcoma. A report of 67 patients and a review of the literature. Cancer 77 : 2400-2406, 1996
 
7) Rosen PP, Kimmel M, Ernsberger D : Mammary angiosarcoma. The prognostic significance of tumor differentiation. Cancer 62 : 2145-2151, 1988
PubMed
8) Nascimento AF, Raut CP, Fletcher CDM : Primary angiosarcoma of the breast : Clinicopathologic analysis of 49 cases, suggesting that grade is not prognostic. Am J Surg Pathol 32 : 1896-1904, 2008
 
9) Meis-Kindblom JM, Kindblom LG : Angiosarcoma of soft tissue. A study of 80 cases. Am J Surg Pathol 22 : 683-697, 1998
 
10) Billings SD, McKenney JK, Folpe AL et al : Cutaneous angiosarcoma following breast-conserving surgery and radiation : An analysis of 27 cases. Am J Surg Pathol 28 : 781-788, 2004
PubMed
11) Fletcher CDM, Beham A, Bekir S et al : Epithelioid angiosarcoma of deep soft tissue : a distinctive tumor readily mistaken for an epithelial neoplasm. Am J Surg Pathol 15 : 915-924, 1991
 
12) Thway K, Billings SD : Angiosarcoma. in WHO Classification of Tumors Editorial Board (ed) : "WHO Classification of Tumours (5th ed). Soft Tissue and Bone Tumours". IARC Press, Lyon, 2020, pp176-178
 
13) Brenn T, Fletcher CDM : Radiation-associated cutaneous atypical vascular lesions and angiosarcoma : Clinicopathologic analysis of 42 cases. Am J Surg Pathol 29 : 983-996, 2005
 
P.85 掲載の参考文献
1) Deyrup AT, Lee VK, Hill CE et al : Epstein-Barr virus-associated smooth muscle tumors are distinctive mesenchymal tumors reflecting multiple infection events : a clinicopathologic and molecular analysis of 29 tumors from 19 patients. Am J Surg Pathol 30 : 75-82, 2006
 
2) Watanabe R, Schafernak KT, Soares FA : EBV-associate smooth muscle tumour. in WHO Classification of Tumours Editorial Board (ed) : "World Health Organization Classification of Tumours. Soft Tissue and Bone Tumours", IARC Press, Lyon, 2020, pp190-192
 
3) Lee ES, Locker J, Nalesnik M et al : The association of Epstein-Barr virus with smooth-muscle tumors occurring after organ transplantation. N Engl J Med 332 : 19-25, 1995
 
4) McClain KL, Leach CT, Jenson HB et al : Association of Epstein-Barr virus with leiomyosarcomas in young people with AIDS. N Engl J Med 332 : 12-18, 1995
PubMed
5) Dalal KM, Antonescu CR, DeMatteo RP et al : EBV-Associated Smooth Muscle Neoplasms : Solid Tumors Arising in the Presence of Immunosuppression and Autoimmune Diseases. Sarcoma 2008 : 859407, 2008
 
6) Jonigk D, Laenger F, Maegel L et al : Molecular and clinicopathological analysis of Epstein-Barr virus-associated posttransplant smooth muscle tumors. Am J Transplant 12 : 1908-1917, 2012
PubMed
7) Rudzinski ER, Lockwood CM, Stohr BA et al : Pan-Trk immunohistochemistry identifies NTRK rearrangements in pediatric mesenchymal tumors. Am J Surg Pathol 42 : 927-935, 2018
PubMed
8) Hung YP, Fletcher CDM, Hornick JL : Evaluation of pan-TRK immunohistochemistry in infantile fibrosarcoma, lipofibromatosis-like neural tumour and histological mimics. Histopthology 73 : 634-644, 2018
 
9) Yamazaki F, Nakatani F, Asano N et al : Novel NTRK3 fusions in fibrosarcomas of adults. Am J Surg Pathol 43 : 523-530, 2019
PubMed
10) Yamamoto H, Yoshida A, Taguchi K et al : ALK, ROS1 and NTRK3 gene rearrangements in inflammatory myofibroblastic tumours. Histopathology 69 : 72-83, 2016
PubMed
11) Yamamoto H, Nozaki Y, Kohashi K et al : Diagnostic utility of pan-Trk immunohistochemistry for inflammatory myofibroblastic tumours. Histopathology 76 : 774-778, 2020
PubMed
12) Fisher C, Montgomery E, Healy V : Calponin and h-caldesmon expression in synovial sarcoma ; the use of calponin in diagnosis. Histopathology 42 : 588-593, 2003
 
13) Kohashi K, Oda Y, Yamamoto H et al : Reduced expression of SMARCB1/INI1 protein in synovial sarcoma. Mod Pathol 23 : 981-990, 2010
PubMed
14) Kadoch C, Crabtree GR : Reversible Disruption of mSWI/SNF (BAF) Complexes by the SS18-SSX Oncogenic Fusion in Synovial Sarcoma. Cell 153 : 71-85, 2013
PubMed
15) Ito J, Asano N, Kawai A et al : The diagnostic utility of reduced immunohistochemical expression of SMARCB1 in synovial sarcomas : a validation study. Hum Pathol 47 : 32-37, 2016
PubMed
16) Baranov E, McBride MJ, Bellizzi AM et al : A Novel SS18-SSX fusion-specific antibody for the diagnosis of synovial sarcoma. Am J Surg Pathol 44 : 922-933, 2020
 
P.90 掲載の参考文献
1) Dry SM, Frohling S : Leiomyosarcoma. World Health Organization Classification of Tumours, Soft Tissue and Bone Tumours. IARC Press, Lyon, 2020, pp195-197
 
2) Yamamoto H, Handa M, Tobo T et al : Clinicopathological features of primary leiomyosarcoma of the gastrointestinal tract following recognition of gastrointestinal stromal tumours. Histopathology 63 : 194-207, 2013
PubMed
3) Gibbons CL, Sun SG, Vlychou M et al : Osteoclast-like cells in soft tissue leiomyosarcomas. Virchows Arch 456 : 317-323, 2010
PubMed
4) Chen E, O'Connell F, Fletcher CD : Dedifferentiated leiomyosarcoma : clinicopathological analysis of 18 cases. Histopathology 59 : 1135-1143, 2011
 
5) Ishii T, Kohashi K, Ootsuka H et al : Comparison between retroperitoneal leiomyosarcoma and dedifferentiated liposarcoma. Pathol Res Pract 213 : 634-638, 2017
PubMed
6) Kohashi K, Oda Y, Yamamoto H et al : Reduced expression of SMARCB1/INI1 protein in synovial sarcoma. Mod Pathol 23 : 981-990, 2010
PubMed
7) Cleven AHG, Al Sannaa GA, Briaire-de Bruijn I et al : Loss of H3K27 tri-methylation is a diagnostic marker for malignant peripheral nerve sheath tumors and an indicator for an inferior survival. Mod Pathol 29 : 582-590, 2016
 
8) Yoshimoto M, Yamada Y, Ishihara S et al : Comparative Study of Myxofibrosarcoma With Undifferentiated Pleomorphic Sarcoma : Histopathologic and Clinicopathologic Review. Am J Surg Pathol 44 : 87-97, 2020
PubMed
P.100 掲載の参考文献
1) Rudzinski ER : Embryonal rhabdomyosarcoma, Kohashi K, Bode-Lesniewska B : Alveolar rhabdomyosarcoma, Montgomery EA, Dry SM : Pleomorphic rhabdomyosarcoma, Agaram NP, Szuhai K : spindle cell/sclerosing rhabdomyosarcoma. in WHO Classification of Tumours Editorial Board (ed) : "Soft Tissue and Bone Tumours, WHO Classification of Tumours (5th ed)", IARC Press, Lyon, 2020, pp201-213
 
2) Newton WA Jr, Gehan EA, Webber BL et al : Classification of rhabdomyosarcomas and related sarcomas. Pathologic aspects and proposal for a new classification--an Intergroup Rhabdomyosarcoma Study. Cancer 76 : 1073-1085, 1995
PubMed
3) Qualman SJ, Coffin CM, Newton WA et al : Intergroup Rhabdomyosarcoma Study : update for pathologists. Pediatr Dev Pathol 1 : 550-561, 1998
 
4) 日本小児血液がん学会監 : 小児腫瘍. 日本癌治療学会, 日本病理学会編 : 領域横断的がん取扱い規約, 第1版, 金原出版, 2019, pp348-350
 
5) Rudzinski ER, Teot LA, Anderson JR et al : Dense pattern of embryonal rhabdomyosarcoma, a lesion easily confused with alveolar rhabdomyosarcoma : a report from the Soft Tissue Sarcoma Committee of the Children's Oncology Group. Am J Clin Pathol 140 : 82-90, 2013
 
6) Alaggio R, Zhang L, Sung YS et al : A Molecular Study of Pediatric Spindle and Sclerosing Rhabdomyosarcoma : Identification of Novel and Recurrent VGLL2-related Fusions in Infantile Cases. Am J Surg Pathol 40 : 224-235, 2016
PubMed
7) Agaram NP, LaQuaglia MP, Alaggio R et al : MYOD1-mutant spindle cell and sclerosing rhabdomyosarcoma : an aggressive subtype irrespective of age. A reappraisal for molecular classification and risk stratification. Mod Pathol 32 : 27-36, 2019
PubMed
8) Kohsaka S, Shukla N, Ameur N et al : A recurrent neomorphic mutation in MYOD1 defines a clinically aggressive subset of embryonal rhabdomyosarcoma associated with PI3K-AKT pathway mutations. Nat Genet 46 : 595-600, 2014
PubMed
9) Agaram NP, Zhang L, Sung YS et al : Expanding the Spectrum of Intraosseous Rhabdomyosarcoma : Correlation Between 2 Distinct Gene Fusions and Phenotype. Am J Surg Pathol 43 : 695-702, 2019
PubMed
10) Qualman S, Lynch J, Bridge J et al : Prevalence and clinical impact of anaplasia in childhood rhabdomyosarcoma : a report from the Soft Tissue Sarcoma Committee of the Children's Oncology Group. Cancer 113 : 3242-3247, 2008
 
11) Kodet R, Newton WA Jr, Hamoudi AB et al : Rhabdomyosarcomas with intermediate-filament inclusions and features of rhabdoid tumors. Light microscopic and immunohistochemical study. Am J Surg Pathol 15 : 257-267, 1991
PubMed
12) Jo VY, Marino-Enriquez A, Fletcher CDM : Epithelioid rhabdomyosarcoma : clinicopathologic analysis of 16 cases of a morphologically distinct variant of rhabdomyosarcoma. Am J Surg Pathol 35 : 1523-1530, 2011
 
13) Boman F, Champigneulle J, Schmitt C et al : Clear cell rhabdomyosarcoma. Pediatr Pathol Lab Med 16 : 951-959, 1996
PubMed
14) Zuppan CW, Mierau GW, Weeks DA : Lipid-rich rhabdomyosarcoma--a potential source of diagnostic confusion. Ultrastruct Pathol 15 : 353-359, 1991
PubMed
15) Cessna MH, Zhou H, Perkins SL et al : Are myogenin and myoD1 expression specific for rhabdomyosarcoma? A study of 150 cases, with emphasis on spindle cell mimics. Am J Surg Pathol 25 : 1150-1157, 2001
PubMed
16) Heerema-McKenney A, Wijnaendts LC, Pulliam JF et al : Diffuse myogenin expression by immunohistochemistry is an independent marker of poor survival in pediatric rhabdomyosarcoma : a tissue microarray study of 71 primary tumors including correlation with molecular phenotype. Am J Surg Pathol 32 : 1513-1522, 2008
PubMed
17) Galili N, Davis RJ, Fredericks WJ et al : Fusion of a fork head domain gene to PAX3 in the solid tumour alveolar rhabdomyosarcoma. Nat Genet 5 : 230-235, 1993
PubMed
18) Davis RJ, D'Cruz CM, Lovell MA et al : Fusion of PAX7 to FKHR by the variant t (1 ; 13) (p36 ; q14) translocation in alveolar rhabdomyosarcoma. Cancer Res 54 : 2869-2872, 1994
 
19) Barr FG, Smith LM, Lynch JC et al : Examination of gene fusion status in archival samples of alveolar rhabdomyosarcoma entered on the Intergroup Rhabdomyosarcoma Study-III trial : a report from the Children's Oncology Group. J Mol Diagn 8 : 202-208, 2006
 
20) Bennicelli JL, Advani S, Schafer BW et al : PAX3 and PAX7 exhibit conserved cis-acting transcription repression domains and utilize a common gain of function mechanism in alveolar rhabdomyosarcoma. Oncogene 18 : 4348-4356, 1999
PubMed
21) Keller C, Arenkiel BR, Coffin CM et al : Alveolar rhabdomyosarcomas in conditional Pax3 : Fkhr mice : cooperativity of Ink4a/ARF and Trp53 loss of function. Genes Dev 18 : 2614-2626, 2004
PubMed
22) Davicioni E, Anderson MJ, Finckenstein FG et al : Molecular classification of rhabdomyosarcoma--genotypic and phenotypic determinants of diagnosis : a report from the Children's Oncology Group. Am J Pathol 174 : 550-564, 2009
 
23) Williamson D, Missiaglia E, de Reynies A et al : Fusion gene-negative alveolar rhabdomyosarcoma is clinically and molecularly indistinguishable from embryonal rhabdomyosarcoma. J Clin Oncol 28 : 2151-2158, 2010
PubMed
24) Davicioni E, Finckenstein FG, Shahbazian V et al : Identification of a PAX-FKHR gene expression signature that defines molecular classes and determines the prognosis of alveolar rhabdomyosarcomas. Cancer Res 66 : 6936-6946, 2006
PubMed
25) Rudzinski ER, Anderson JR, Lyden ER et al : Myogenin, AP2β, NOS-1, and HMGA2 are surrogate markers of fusion status in rhabdomyosarcoma : a report from the soft tissue sarcoma committee of the Children's Oncology Group. Am J Surg Pathol 38 : 654-659, 2014
 
26) Kaleta M, Wakuli ska A, Karkuci ska-Wi ckowska A et al : OLIG2 is a novel immunohistochemical marker associated with the presence of PAX3/7-FOXO1 translocation in rhabdomyosarcomas. Diagn Pathol 14 : 103, 2019
 
P.108 掲載の参考文献
1) Hruban RH, Shiu MH, Senie RT et al : Malignant peripheral nerve sheath tumors of the buttock and lower extremity : a study of 43 cases. Cancer 66 : 1253-1265, 1990
PubMed
2) Zou C, Smith KD, Liu J et al : Clinical, pathological, and molecular variables predictive of malignant peripheral nerve sheath tumor outcome. Ann Surg 249 : 1014-1022, 2009
PubMed
3) Evans DG, Baser ME, McGaughran J et al : Malignant peripheral nerve sheath tumours in neurofibromatosis 1. J Med Genet 39 : 311-314, 2002
PubMed
4) Ducetman BS, Scheithauer BW, Piepgras DG et al : Malignant peripheral nerve sheath tumors. A clinicopathologic study of 120 cases. Cancer 57 : 2006-2021, 1986
 
5) Schaefer IM, Fletcher CDM, Hornick JL : Loss of H3K27 trimethylation distinguishes malignant peripheral nerve sheath tumors from histologic mimics. Mod Pathol 29 : 4-13, 2016
 
6) Prieto-Granada CN, Wiesner T, Messina JL et al : Loss of H3K27me3 expression is a highly sensitive marker for sporadic and radiation-induced MPNST. Am J Surg Pathol 40 : 479-489, 2016
PubMed
7) Hirose T, Scheithauer BW, Sano T : Perineurial malignant peripheral nerve sheath tumor (MPNST) : a clinicopathologic, immunohistochemical, and ultrastructural study of seven cases. Am J Surg Pathol 22 : 1368-1378, 1998
PubMed
8) Le Guellec S, Macagno N, Velasco V et al : Loss of H3K27 trimethylation is not suitable for distinguishing malignant peripheral nerve sheath tumor from melanoma : a study of 387 cases including mimicking lesions. Mod Pathol 30 : 1677-1687, 2017
 
9) Sawada S, Florell S, Purandare SM et al : Identification of NF1 mutations in both alleles of a dermal neurofibroma. Nat Genet 14 : 110-112, 1996
PubMed
10) Menon AG, Anderson KM, Riccardi VM et al : Chromosome 17p deletions and p53 gene mutations associated with the formation of malignant neurofibrosarcomas in von Recklinghausen neurofibromatosis. Proc Natl Acad Sci U S A 87 : 5435-5439, 1990
 
11) Lee W, Teckie S, Wiesner T et al : PRC2 is recurrently inactivated through EED or SUZ12 loss in malignant peripheral nerve sheath tumors. Nat Genet 46 : 1227-1232, 2014
PubMed
12) De Raedt T, Beert E, Pasmant E et al : PRC2 loss amplifies Ras-driven transcription and confers sensitivity to BRD4-based therapies. Nature 514 : 247-251, 2014
PubMed
13) Miettinen MM, Antonescu CR, Fletcher CDM et al : Histopathologic evaluation of atypical neurofibromatous tumors and their transformation into malignant peripheral nerve sheath tumor in patients with neurofibromatosis 1-a consensus overview. Hum Pathol 67 : 1-10, 2017
PubMed
14) Beert E, Brems H, Daniels B et al : Atypical neurofibromas in neurofibromatosis type 1 are premalignant tumors. Genes Chromosomes Cancer 50 : 1021-1032, 2011
PubMed
15) Goldblum JR, Folpe AL, Weiss SW : Enzinger & Weiss's Soft Tissue Tumors, 7th ed, Elsevier, Philadelphia, 2020, pp906-912
 
P.112 掲載の参考文献
1) Nielsen GP, O'Connell JX, Rosenberg AE : Intramuscular myxoma : a clinicopathologic study of 51 cases with emphasis on hypercellular and hypervascular variants. Am J Surg Pathol 22 : 1222-1227, 1998
 
2) Hashimoto H, Tsuneyoshi M, Daimaru Y et al : Intramuscular myxoma. A clinicopathologic, immunohistochemical, and electron microscopic study. Cancer 58 : 740-747, 1986
PubMed
3) van Roggen JF, McMenamin ME, Fletcher CD : Cellular myxoma of soft tissue : a clinicopathological study of 38 cases confirming indolent clinical behavior. Histopathology 39 : 287-297, 2001
 
4) Majoor BCJ, van de Sande MAJ, Appelman-Dijkstra NM et al : Prevalence and Clinical Features of Mazabraud Syndrome : A Multicenter European Study. J Bone Joint Surg Am 101 : 160-168, 2019
PubMed
5) Zoccali C, Teori G, Prencipe U et al : Mazabraud's syndrome : a new case and review of the literature. Int Orthop 33 : 605-610, 2009
 
6) Libbrecht L, Bempt IV, Schubert T et al : Next generation sequencing for GNAS uncovers CD34 as a sensitive marker for intramuscular myxoma. Ann Diagn Pathol 43 : 151409, 2019
PubMed
7) Okamoto S, Hisaoka M, Ushijima M et al : Activating Gsα mutation in intramuscular myxomas with and without fibrous dysplasia of bone. Virchows Arch 437 : 133-137, 2000
 
8) Willems SM, Mohseny AB, Balog C et al : Cellular/intramuscular myxoma and grade I myxofibrosarcoma are characterized by distinct genetic alterations and specific composition of their extracellular matrix. J Cell Mol Med 13 : 1291-1301, 2009
 
9) Bekers EM, Eijkelenboom A, Rombout P et al : Identification of novel GNAS mutations in intramuscular myxoma using next-generation sequencing with single-molecule tagged molecular inversion probes. Diagn Pathol 14 : 15, 2019
PubMed
10) Yoshimoto M, Yamada Y, Ishihara S et al : Comparative Study of Myxofibrosarcoma With Undifferentiated Pleomorphic Sarcoma : Histopathologic and Clinicopathologic Review. Am J Surg Pathol 44 : 87-97, 2020
PubMed
11) Doyle LA, Moller E, Dal Cin P et al : MUC4 Is a Highly Sensitive and Specific Marker for Low-grade Fibromyxoid Sarcoma. Am J Surg Pathol 35 : 733-741, 2011
PubMed
12) Antonescu CR, Tschernyavsky SJ, Decuseara R et al : Prognostic impact of P53 status, TLS-CHOP fusion transcript structure, and histological grade in myxoid liposarcoma : a molecular and clinicopathologic study of 82 cases. Clin Cancer Res 7 : 3977-3987, 2001
PubMed
P.118 掲載の参考文献
1) Rekhi B, Antonescu CR, Chen G : Angiomatoid fibrous histiocytoma. in Antonescu CR, Blay JV, Bovee JVMG et al (eds) : "World Health Organization Classification of Tumours・5th edition. Soft Tissue and Bone Tumours", IARC Press, Lyon, 2020, pp271-273
 
2) Enzinger FM : Angiomatoid malignant fibrous histiocytoma : a distinct fibrohistiocytic tumor of children and young adults simulating a vascular neoplasm. Cancer 44 : 2147-2157, 1979
 
3) Hasegawa T, Seki K, Ono K et al : Angiomatoid (malignant) fibrous histiocytoma : a peculiar low-grade tumor showing immunophenotypic heterogeneity and ultrastructural variations. Pathol Int 50 : 731-738, 2000
PubMed
4) Chen G, Folpe AL, Colby TV et al : Angiomatoid fibrous histiocytoma : unusual sites and unusual morphology. Mod Pathol 24 : 1560-1570, 2011
PubMed
5) Kao YC, Lan J, Tai HC et al : Angiomatoid fibrous histiocytoma : clinicopathological and molecular characterisation with emphasis on variant histomorphology. J Clin Pathol 67 : 210-215, 2014
PubMed
6) Schaefer IM, Fletcher CDM : Myxoid variant of so-called angiomatoid "malignant fibrous histiocytoma" : clinicopathologic characterization in a series of 21 cases. Am J Surg Pathol 38 : 816-823, 2014
 
7) Antonescu CR, Dal Cin P, Nafa K et al : EWSR1-CREB1 is the predominant gene fusion in angiomatoid fibrous histiocytoma. Genes Chromosomes Cancer 46 : 1051-1060, 2007
PubMed
8) Matsumura T, Yamaguchi T, Tochigi N et al : Angiomatoid fibrous histiocytoma including cases with pleomorphic features analysed by fluorescence in situ hybridization. J Clin Pathol 63 : 124-128, 2010
PubMed
9) Thway K, Fisher C : Angiomatoid fibrous histiocytoma : the current status of pathology and genetics. Arch Pathol Lab Med 139 : 674-682, 2015
PubMed
10) Yoshida A, Wakai S, Ryo E et al : Expanding the phenotypic spectrum of mesenchymal tumors harboring the EWSR1-CREM fusion. Am J Surg Pathol 43 : 1622-1630, 2019
PubMed
11) Kao YC, Sung YS, Zhang L et al : EWSR1 fusions with CREB family transcription factors define a novel myxoid mesenchymal tumor with predilection for intracranial location. Am J Surg Pathol 41 : 482-490, 2017
PubMed
12) Ghanbari N, Lam A, Wycoco V et al : Intracranial myxoid variant of angiomatoid fibrous histiocytoma : a case report and literature review. Cureus 11 : e4261, 2019
PubMed
P.124 掲載の参考文献
1) Kilpatrick SE, Hitchcock MG, Kraus MD et al : Mixed tumors and myoepitheliomas of soft tissue : a clinicopathologic study of 19 cases with a unifying concept. Am J Surg Pathol 21 : 13-22, 1997
 
2) Dabska M : Parachordoma : a new clinicopathologic entity. Cancer 40 : 1586-1592, 1977
PubMed
3) Gleason BC, Fletcher CDM : Myoepithelial carcinoma of soft tissue in children : an aggressive neoplasm analyzed in a series of 29 cases. Am J Surg Pathol 31 : 1813-1824, 2007
 
4) Segawa K, Sugita S, Aoyama T et al : Myoepithelioma of soft tissue and bone, and myoepithelioma-like tumors of the vulvar region : Clinicopathological study of 15 cases by PLAG1 immunohistochemistry. Pathol Int 70 : 965-974, 2020
PubMed
5) Jo VY, Fletcher CDM : Myoepithelial neoplasms of soft tissue : an updated review of the clinicopathologic, immunophenotypic, and genetic features. Head Neck Pathol 9 : 32-38, 2015
 
6) Huang SC, Chen HW, Zhang L et al : Novel FUS-KLF17 and EWSR1-KLF17 fusions in myoepithelial tumors. Genes Chromosomes Cancer 54 : 267-275, 2015
PubMed
7) Urbini M, Astolfi A, Indio V et al : Identification of SRFE2F1 fusion transcript in EWSR-negative myoepithelioma of the soft tissue. Oncotarget 8 : 60036-60045, 2017
PubMed
8) Bahrami A, Dalton JD, Krane JF et al : A subset of cutaneous and soft tissue mixed tumors are genetically linked to their salivary gland counterpart. Genes Chromosomes Cancer 51 : 140-148, 2012
PubMed
9) Antonescu CR, Zhang L, Shao SY et al : Frequent PLAG1 gene rearrangements in skin and soft tissue myoepithelioma with ductal differentiation. Genes Chromosomes Cancer 52 : 675-682, 2013
PubMed
10) Yoshida A, Yoshida H, Yoshida M et al : Myoepithelioma-like tumors of the vulvar region : A distinctive group of SMARCB1-deficient neoplasms. Am J Surg Pathol 39 : 1102-1113, 2015
PubMed
P.127 掲載の参考文献
1) Prader A, Illig R, Uehlinger E et al : Rickets following bone tumor. Helv Paediatr Acta 14 : 554-565, 1959
PubMed
2) Weidner N, Santa Crus D : Phosphaturic mesenchymal tumors. A polymorphous group causing osteomalacia or rickets. Cancer 59 : 1442-1454, 1987
PubMed
3) Cai Q, Hodgson SF, Kao PC et al : Brief report : inhibition of renal phosphate transport by a tumor product in a patient with oncogenic osteomalacia. N Engl J Med 330 : 1645-1649, 1994
 
4) Shimada T, Mizutani S, Muto T et al : Cloning and characterization of FGF23 as a causative factor of tumor-induced osteomalacia. Proc Natl Acad Sci U S A 98 : 6500-6505, 2001
PubMed
5) Boland JM, Tebben PJ, Folpe AL : Phosphaturic mesenchymal tumors : what an endocrinologist should know. J Endocrinol Invest 41 : 1173-1184, 2018
 
6) 石田剛, 鹿島健司, 町並陸生 : 腫瘍に伴う骨軟化症・くる病の病理. 病理と臨床 17 : 23-27, 1999
Medical*Online
7) 石田剛 : 骨腫瘍の病理, 文光堂, 2012, pp391-395
 
8) Folpe AL, Fanburg-Smith JC, Billings SD et al : Most osteomalacia-associated mesenchymal tumors are a single histopathologic entity : an analysis of 32 cases and a comprehensive review of the literature. Am J Surg Pathol 28 : 1-30, 2004
 
9) Shiba E, Matsuyama A, Shibuya R et al : Immunohistochemical and molecular detection of the expression of FGF23 in phosphaturic mesenchymal tumors including the non-phosphaturic variant. Diagn Pathol 11 : 26, 2016
PubMed
10) Lee JC, Su SY, Changou CA et al : Characterization of FN1-FGFR1 and novel FN1-FGF1 fusion genes in a large series of phosphaturic mesenchymal tumors. Mod Pathol 29 : 1335-1346, 2016
 
11) Lee JC, Jeng YM, Su SY et al : Identification of a novel FN1-FGFR1 genetic fusion as a frequent event in phosphaturic mesenchymal tumour. J Pathol 235 : 539-545, 2015
PubMed
12) Lee CH, Su SY, Sittampalam K et al : Frequent overexpression of klotho in fusion-negative phosphaturic mesenchymal tumors with tumorigenic implications. Mod Pathol 33 : 858-870, 2020
PubMed
P.132 掲載の参考文献
1) Suurmeijer AJH, Antonescu CR : NTRK-rearranged spindle cell neoplasm (emerging). Antonescu CR, Bridge JA, Cunha IW et al (eds) : WHO classification of Tumours. Soft Tissue and Bone Tumours, 5th ed, IARC Press, 2020, pp287-289
 
2) Agaram NP, Zhang L, Sung YS et al : Recurrent NTRK1 gene fusions define a novel subset of locally aggressive lipofibromatosis-like neural tumors. Am J Surg Pathol 40 : 1407-1416, 2016
PubMed
3) Suurmeijer AJH, Dickson BC, Swanson D et al : A novel group of spindle cell tumors defined by S100 and CD34 co-expression shows recurrent fusions involving RAF1, BRAF, and NTRK1/2 genes. Genes Chromosomes Cancer 57 : 611-621, 2018
 
4) Suurmeijer AJ, Dickson BC, Swanson D et al : The histologic spectrum of soft tissue spindle cell tumors with NTRK3 gene rearrangements. Genes Chromosomes Cancer 58 : 739-746, 2019
PubMed
5) Haller F, Knopf J, Ackermann A et al : Paediatric and adult soft tissue sarcomas with NTRK1 gene fusions : a subset of spindle cell sarcomas unified by a prominent myopericytic/haemangiopericytic pattern. J Pathol 238 : 700-710, 2016
PubMed
6) Yamazaki F, Nakatani F, Asano N et al : Novel NTRK3 fusions in fibrosarcomas of adults. Am J Surg Pathol 43 : 523-530, 2019
PubMed
7) Davis JL, Lockwood CM, Stohr B et al : Expanding the spectrum of pediatric NTRK-rearranged mesenchymal tumors. Am J Surg Pathol 43 : 435-445, 2019
PubMed
8) Church AJ, Calicchio ML, Nardi V et al : Recurrent EML4-NTRK3 fusions in infantile fibrosarcoma and congenital mesoblastic nephroma suggest a revised testing strategy. Mod Pathol 31 : 463-473, 2018
PubMed
9) Chiang S, Cotzia P, Hyman DM et al : NTRK fusions define a novel uterine sarcoma subtype with features of fibrosarcoma. Am J Surg Pathol 42 : 791-798, 2018
PubMed
10) Penault-Llorca F, Rudzinski ER, Sepulveda AR : Testing algorithm for identification of patients with TRK fusion cancer. J Clin Pathol 72 : 460-467, 2019
 
11) Solomon JP, Hechtman JF : Detection of NTRK fusions : merits and limitations of current diagnostic platforms. Cancer Res 79 : 3163-3168, 2019
PubMed
12) Hechtman JF, Benayed R, Hyman DM et al : Pan-Trk immunohistochemistry is an efficient and reliable screen for the detection of NTRK fusions. Am J Surg Pathol 41 : 1547-1551, 2017
PubMed
13) Hung YP, Fletcher CDM, Hornick JL : Evaluation of pan-TRK immunohistochemistry in infantile fibrosarcoma, lipofibromatosis-like neural tumour and histological mimics. Histopathology 73 : 634-644, 2018
PubMed
14) Solomon JP, Linkov I, Rosado A et al : NTRK fusion detection across multiple assays and 33,997 cases : diagnostic implications and pitfalls. Mod Pathol 33 : 38-46, 2020
PubMed
15) Yamamoto H, Nozaki Y, Kohashi K et al : Diagnostic utility of pan-Trk immunohistochemistry for inflammatory myofibroblastic tumours. Histopathology 76 : 774-778, 2020
PubMed
16) Rudzinski ER, Lockwood CM, Stohr BA et al : Pan-Trk immunohistochemistry identifies NTRK rearrangements in pediatric mesenchymal tumors. Am J Surg Pathol 42 : 927-935, 2018
PubMed
17) Cocco E, Scaltriti M, Drilon A : NTRK fusion-positive cancers and TRK inhibitor therapy. Nat Rev Clin Oncol 15 : 731-747, 2018
PubMed
P.142 掲載の参考文献
1) WHO Classification of Tumours, Soft Tissue and Bone Tumours 5th edition, IARC, Lyon, 2020
 
2) Smith LW : Synoviomata. Am J Pathol 3 : 355-364, 1927
PubMed
3) Miettinen M, Virtanen I : Synovial sarcoma-a misnomer. Am J Pathol 117 : 18-25, 1984
PubMed
4) Goldblum JR, Folpe AL, Weiss SW (eds) : Enzinger & Weiss's soft tissue tumors, 7th ed, Elsevier, Philadelphia, 2020
 
5) Makhlouf HR, Ahrens W, Agarwal B et al : Synovial sarcoma of the stomach : a clinicopathologic, immunohistochemical, and molecular genetic study of 10 cases. Am J Surg Pathol 32 : 275-281, 2008
PubMed
6) van de Rijn M, Barr FG, Xiong QB et al : Poorly differentiated synovial sarcoma : an analysis of clinical, pathologic, and molecular genetic features. Am J Surg Pathol 23 : 106-112, 1999
PubMed
7) Miettinen M : Keratin subsets in spindle cell sarcomas. Keratins are widespread but synovial sarcoma contains a distinctive keratin polypeptide pattern and desmoplakins. Am J Pathol 138 : 505-513, 1991
PubMed
8) Baranov E, McBride MJ, Bellizzi AM et al : A Novel SS18-SSX Fusion-specific Antibody for the Diagnosis of Synovial Sarcoma. Am J Surg Pathol 44 : 922-933, 2020
 
9) Dei Tos AP, Wadden C, Calonje E et al : Immunohistochemical demonstration of glycoprotein p30/32 (MIC2) (CD99) in synovial sarcoma : A poteintial cause of diagnostic confusion. Appl Immunohistochem 3 : 168-173, 1995
 
10) Terry J, Saito T, Subramanian S et al : TLE1 as a diagnostic immunohistochemical marker for synovial sarcoma emerging from gene expression profiling studies. Am J Surg Pathol 31 : 240-246, 2007
PubMed
11) Kosemehmetoglu K, Vrana JA, Folpe AL : TLE1 expression is not specific for synovial sarcoma : a whole section study of 163 soft tissue and bone neoplasms. Mod Pathol 22 : 872-878, 2009
 
12) Ito J, Asano N, Kawai A et al : The diagnostic utility of reduced immunohistochemical expression of SMARCB1 in synovial sarcomas : a validation study. Hum Pathol 47 : 32-37, 2016
PubMed
13) Sandberg AA, Bridge JA : Updates on the cytogenetics and molecular genetics of bone and soft tissue tumors. Synovial sarcoma. Cancer Genet Cytogenet 133 : 1-23, 2002
PubMed
14) Antonescu CR : The role of genetic testing in soft tissue sarcoma. Histopathology 48 : 13-21, 2006
PubMed
15) Banito A, Li X, Laporte AN et al : The SS18-SSX Oncoprotein Hijacks KDM2B-PRC1.1 to Drive Synovial Sarcoma [published correction appears in Cancer Cell 34 : 346-348]. Cancer Cell 33 : 527-541.e8, 2018
 
16) Kawai A, Woodruff J, Healey JH et al : SYT-SSX gene fusion as a determinant of morphology and prognosis in synovial sarcoma. N Engl J Med 338 : 153-160, 1998
PubMed
17) Tsuji S, Hisaoka M, Morimitsu Y et al : Detection of SYT-SSX fusion transcripts in synovial sarcoma by reverse transcription-polymerase chain reaction using archival paraffin-embedded tissues. Am J Pathol 153 : 1807-1812, 1998
PubMed
18) Terry J, Barry TS, Horsman DE et al : Fluorescence in situ hybridization for the detection of t (X ; 18) (p11.2 ; q11.2) in a synovial sarcoma tissue microarray using a breakapart-style probe. Diagn Mol Pathol 14 : 77-82, 2005
 
19) Motoi T, Kumagai A, Tsuji K et al : Diagnostic utility of dual-color break-apart chromogenic in situ hybridization for the detection of rearranged SS18 in formalin-fixed, paraffin-embedded synovial sarcoma. Hum Pathol 41 : 1397-1404, 2010
PubMed
20) Ishida T, Kojima T, Iijima T et al : Synovial Sarcoma With a Predominant Epithelial Component. Int J Surg Pathol 1 : 261-267, 1994
 
21) Miettinen M, Limon J, Niezabitowski A et al : Calretinin and other mesothelioma markers in synovial sarcoma : analysis of antigenic similarities and differences with malignant mesothelioma. Am J Surg Pathol 25 : 610-617, 2001
PubMed
22) Coindre JM, Hostein I, Benhattar J et al : Malignant peripheral nerve sheath tumors are t (X ; 18) -negative sarcomas. Molecular analysis of 25 cases occurring in neurofibromatosis type 1 patients, using two different RT-PCR-based methods of detection. Mod Pathol 15 : 589-592, 2002
 
23) Krane JF, Bertoni F, Fletcher CD : Myxoid synovial sarcoma : an underappreciated morphologic subset. Mod Pathol 12 : 456-462, 1999
PubMed
24) Folpe AL, Schmidt RA, Chapman D et al : Poorly differentiated synovial sarcoma : immunohistochemical distinction from primitive neuroectodermal tumors and high-grade malignant peripheral nerve sheath tumors. Am J Surg Pathol 22 : 673-682, 1998
PubMed
P.148 掲載の参考文献
1) Guillou L, Wadden C, Coindre JM et al : "Proximal-type" epithelioid sarcoma, a distinctive aggressive neoplasm showing rhabdoid features. Clinicopathologic, immunohistochemical, and ultrastructural study of a series. Am J Surg Pathol 21 : 130-146, 1997
PubMed
2) Oda Y, Nielsen TO, Cin PD, Loarer FL : Epithelioid sarcoma. in WHO Classification of Tumours Editorial Board (eds) : "World Health Organization Classification of Tumours. Soft Tissue and Bone Tumours (5th ed)", IARC Press, Lyon, 2020, pp294-296
 
3) Miettinen M, Fanburg-Smith JC, Virolainen M et al : Epithelioid sarcoma : an immunohistochemical analysis of 112 classical and variant cases and a discussion of the differential diagnosis. Hum Pathol 30 : 934-942, 1999
 
4) Hasegawa T, Matsuno Y, Shimoda T et al : Proximal-type epithelioid sarcoma : a clinicopathologic study of 20 cases. Mod Pathol 14 : 655-663, 2001
PubMed
5) Izumi T, Oda Y, Hasegawa T et al : Prognostic significance of dysadherin expression in epithelioid sarcoma and its diagnostic utility in distinguishing epithelioid sarcoma from malignant rhabdoid tumor. Mod Pathol 19 : 820-831, 2006
 
6) Kohashi K, Izumi T, Oda Y et al : Infrequent SMARCB1/INI1 gene alteration in epithelioid sarcoma : a useful tool in distinguishing epithelioid sarcoma from malignant rhabdoid tumor. Hum Pathol 40 : 349-355, 2009
PubMed
7) Oda Y, Tsuneyoshi M : Extrarenal rhabdoid tumors of soft tissue : clinicopathological and molecular genetic review and distinction from other soft-tissue sarcomas with rhabdoid features. Pathol Int 56 : 287-295, 2006
PubMed
8) Chbani L, Guillou L, Terrier P et al : Epithelioid sarcoma : a clinicopathologic and immunohistochemical analysis of 106 cases from the French sarcoma group. Am J Clin Pathol 131 : 222-227, 2009
 
9) Humble SD, Prieto VG, Horenstein MG : Cytokeratin 7 and 20 expression in epithelioid sarcoma. J Cutan Pathol 30 : 242-246, 2003
PubMed
10) Laskin WB, Miettinen M : Epithelioid sarcoma : new insights based on an extended immunohistochemical analysis. Arch Pathol Lab Med 127 : 1161-1168, 2003
 
11) Lin L, Skacel M, Sigel JE et al : Epithelioid sarcoma : an immunohistochemical analysis evaluating the utility of cytokeratin 5/6 in distinguishing superficial epithelioid sarcoma from spindled squamous cell carcinoma. J Cutan Pathol 30 : 114-117, 2003
PubMed
12) Saito T, Oda Y, Itakura E et al : Expression of intercellular adhesion molecules in epithelioid sarcoma and malignant rhabdoid tumor. Pathol Int 51 : 532-542, 2001
PubMed
13) Kohashi K, Yamada Y, Hotokebuchi Y et al : ERG and SALL4 expressions in SMARCB1/INI1-deficient tumors : a useful tool for distinguishing epithelioid sarcoma from malignant rhabdoid tumor. Hum Pathol 46 : 225-230, 2015
PubMed
14) Yoshida A, Asano N, Kawai A et al : Differential SALL4 immunoexpression in malignant rhabdoid tumours and epithelioid sarcomas. Histopathology 66 : 252-261, 2015
PubMed
15) Kohashi K, Nakatsura T, Kinoshita Y et al : Glypican 3 expression in tumors with loss of SMARCB1/INI1 protein expression. Hum Pathol 44 : 526-533, 2013
PubMed
16) Hollmann TJ, Hornick JL : INI1-Deficient Tumors : Diagnostic Features and Molecular Genetics. Am J Surg Pathol 35 : e47-e63, 2011
PubMed
17) Kohashi K, Oda Y : Oncogenic roles of SMARCB1/INI1 and its deficient tumors. Cancer Sci 108 : 547-552, 2017
PubMed
18) Hornick JL, Bovee JVMG, Agaram NP : Pseudomyogenic hemangioendothelioma. in WHO Classification of Tumours Editorial Board (eds) : "World Health Organization Classification of Tumours. Soft Tissue and Bone Tumours (5th ed)", IARC Press, Lyon, 2020, pp169-171
 
19) Sapi Z, Papp G, Szendroi M et al : Epigenetic regulation of SMARCB1 By miR-206, -381 and -671-5p is evident in a variety of SMARCB1 immunonegative soft tissue sarcomas, while miR-765 appears specific for epithelioid sarcoma. A miRNA study of 223 soft tissue sarcomas. Genes Chromosomes Cancer 55 : 786-802, 2016
 
P.154 掲載の参考文献
1) Christopherson WM, Foote FW Jr, Stewart FW : Alveolar soft-part sarcomas. Structurally characteristic tumors of uncertain histogenesis. Cancer 5 : 100-111, 1952
 
2) Shipkey FH, Lieberman PH, Foote FW Jr et al : Ultrastructure of alveolar soft part sarcoma. Cancer 17 : 821-830, 1964
PubMed
3) Jambhekar NA, Ladanyi M : Alveolar soft part sarcoma. in The WHO classification of tumors editorial board (eds) : "World Health Organization classification of tumours. Soft tissue and bone tumours", IARC Press, Lyon, 2020, pp297-299
 
4) Weiss SW, Goldblum JR : Enzinger and Weiss's soft tissue tumors (5th ed), Mosby, St Louis, 2008, pp1182-1191
 
5) Ladanyi M, Lui MY, Antonescu CR et al : The der (17) t (X ; 17) (p11 ; q25) of human alveolar soft part sarcoma fuses the TFE3 transcription factor gene to ASPL, a novel gene at 17q25. Oncogene 20 : 48-57, 2001
PubMed
6) Lieberman PH, Brennan MF, Kimmel M et al : Alveolar soft-part sarcoma. A clinico-pathologic study of half a century. Cancer 63 : 1-13, 1989
PubMed
7) Ogose A, Yazawa Y, Ueda T et al : Alveolar soft part sarcoma in Japan : multi-institutional study of 57 patients from the Japanese Musculoskeletal Oncology Group. Oncology 65 : 7-13, 2003
PubMed
8) Suh JS, Cho J, Lee SH et al : Alveolar soft part sarcoma : MR and angiographic findings. Skeletal Radiol 29 : 680-689, 2000
PubMed
9) Ladanyi M, Antonescu CR, Drobnjak M et al : The precrystalline cytoplasmic granules of alveolar soft part sarcoma contain monocarboxylate transporter 1 and CD147. Am J Pathol 160 : 1215-1221, 2002
PubMed
10) Argani P, Lal P, Hutchinson B et al : Aberrant nuclear immunoreactivity for TFE3 in neoplasms with TFE3 gene fusions. A sensitive and specific immunohistochemical assay. Am J Surg Pathol 27 : 750-761, 2003
PubMed
11) Sharain RF, Gown AM, Greipp PT et al : Immunohistochemistry for TFE3 lacks specificity and sensitivity in the diagnosis of TFE3-rearranged neoplasms : a comparative, 2-laboratory study. Hum Pathol 87 : 65-74, 2019
 
12) Tsuda M, Davis IJ, Argani P et al : TFE3 fusions activate MET signaling by transcriptional up-regulation, defining another class of tumors as candidates for therapeutic MET inhibition. Cancer Res 67 : 919-929, 2007
PubMed
13) Tanaka M, Homme M, Yamazaki Y et al : Modeling Alveolar Soft Part Sarcoma Unveils Novel Mechanisms of Metastasis. Cancer Res 77 : 897-907, 2017
PubMed
14) Ishiguro N, Yoshida H : ASPL-TFE3 Oncoprotein Regulates Cell Cycle Progression and Induces Cellular Senescence by Up-Regulating p21. Neoplasia 18 : 626-635, 2016
PubMed
15) Lazar AJ, Lahat G, Myers SE et al : Validation of potential therapeutic targets in alveolar soft part sarcoma : an immunohistochemical study utilizing tissue microarray. Histopathology 55 : 750-755, 2009
PubMed
16) Stacchiotti S, Tamborini E, Marrari A et al : Response to sunitinib malate in advanced alveolar soft part sarcoma. Clin Cancer Res 15 : 1096-1104, 2009
PubMed
17) Azizi AA, Haberler C, Czech T et al : Vascular-endothelial-growth-factor (VEGF) expression and possible response to angiogenesis inhibitor bevacizumab in metastatic alveolar soft part sarcoma. Lancet Oncol 7 : 521-523, 2006
PubMed
18) Wilky BA, Trucco MM, Subhawong TK et al : Axitinib plus pembrolizumab in patients with advanced sarcomas including alveolar soft-part sarcoma : a single-centre, single-arm, phase 2 trial. Lancet Oncol 20 : 837-848, 2019
PubMed
P.161 掲載の参考文献
1) Fritchie KJ, van de Rijn M : Clear cell sarcoma. in "WHO Classification of Tumours. Soft Tissue and Bone Tumours", 5th edition, IARC, Lyon, 2020, pp300-302
 
2) Enzinger FM : Clear-cell sarcoma of tendons and aponeuroses. An analysis of 21 cases. Cancer 18 : 1163-1174, 1965
PubMed
3) Zucman J, Delattre O, Desmaze C et al : EWS and ATF-1 gene fusion induced by t (12 ; 22) translocation in malignant melanoma of soft parts. Nat Genet 4 : 341-345, 1993
 
4) Hisaoka M, Ishida T, Kuo TT et al : Clear cell sarcoma of soft tissue : a clinicopathologic, immunohistochemical, and molecular analysis of 33 cases. Am J Surg Pathol 32 : 452-460, 2008
PubMed
5) Chang B, Yu L, Guo WW et al : Malignant Gastrointestinal Neuroectodermal Tumor : Clinicopathologic, Immunohistochemical, and Molecular Analysis of 19 Cases. Am J Surg Pathol 44 : 456-466, 2020
 
6) Wang WL, Mayordomo E, Zhang W et al : Detection and characterization of EWSR1/ATF1 and EWSR1/CREB1 chimeric transcripts in clear cell sarcoma (melanoma of soft parts). Mod Pathol 22 : 1201-1209, 2009
PubMed
7) Hantschke M, Mentzel T, Rutten A et al : Cutaneous clear cell sarcoma : a clinicopathologic, immunohistochemical, and molecular analysis of 12 cases emphasizing its distinction from dermal melanoma. Am J Surg Pathol 34 : 216-222, 2010
PubMed
8) Deyrup AT, Althof P, Zhou M et al : Paraganglioma-like dermal melanocytic tumor : a unique entity distinct from cellular blue nevus, clear cell sarcoma, and cutaneous melanoma. Am J Surg Pathol 28 : 1579-1586, 2004
PubMed
9) Kashima J, Motoi T, Nishimaki M et al : A case report of cutaneous melanocytoma with CRTC1-TRIM11 fusion : Is CMCT distinct from clear cell sarcoma of soft tissue? Pathol Int 69 : 496-501, 2019
PubMed
10) Yoshida A, Wakai S, Ryo E et al : Expanding the Phenotypic Spectrum of Mesenchymal Tumors Harboring the EWSR1-CREM Fusion. Am J Surg Pathol 43 : 1622-1630, 2019
PubMed
P.167 掲載の参考文献
1) Stout AP, Verner EW : Chondrosarcoma of the extraskeletal soft tissues. Cancer 6 : 581-590, 1953
PubMed
2) Goldenberg RR, Cohen P, Steinlauf P : Chondrosarcoma of the extraskeletal soft tissues. A report of seven cases and review of the literature. J Bone Joint Surg Am 49 : 1487-1507, 1967
PubMed
3) Enzinger FM, Shiraki M : Extraskeletal myxoid chondrosarcoma. An analysis of 34 cases. Hum Pathol 3 : 421-435, 1972
PubMed
4) Stewart FW : Case 211. Division of Laboratories and Research, Albany, New York, 1948
 
5) Martin RF, Melnick PJ, Warner NE et al : Chordoid Sarcoma. Am J Clin Pathol 59 : 623-635, 1973
PubMed
6) Weiss SW : Ultrastructure of the so-called "chordoid sarcoma". Evidence supporting cartilagenous differentiation. Cancer 37 : 300-306, 1976
PubMed
7) Hisaoka M, Hashimoto H : Extraskeletal myxoid chondrosarcoma : updated clinicopathological and molecular genetic characteristics. Pathol Int 55 : 453-463, 2005
PubMed
8) Goh YW, Spagnolo DV, Platten M et al : Extraskeletal Myxoid Chondrosarcoma : A Light Microscopic, Immunohistochemical, Ultrastructural and Immuno-Ultrastructural Study Indicating Neuroendocrine Differentiation. Histopathology 39 : 514-524, 2001
PubMed
9) Yoshida A, Makise N, Wakai S et al : INSM1 expression and its diagnostic significance in extraskeletal myxoid chondrosarcoma. Mod Pathol 31 : 744-752, 2018
PubMed
10) Horvai AE, Agaram NP, Lucas DR : Extraskeletal myxoid chondrosarcoma. in : Lokuhetty D, White VA, Cree IA (eds) : World Health Organization Classification of Tumour, Soft Tissue and Bone Tumours, IARC Press, Lyon, 2020, pp303-305
 
11) Hinrichs SH, Jaramillo MA, Gumerlock PH et al : Myxoid chondrosarcoma with a translocation involving chromosomes 9 and 22. Cancer Genet Cytogenet 14 : 219-226, 1985
PubMed
12) Goldblum JR, Folpe AL, Weiss SW : Enzinger and Weiss's Soft Tissue Tumors (7th ed), Elsevier, Philaderphia, 2020, pp1194-1200
 
13) Meis-Kindblom JM, Bergh P, Gunterberg B et al : Extraskeletal myxoid chondrosarcoma : a reappraisal of its morphologic spectrum and prognostic factors based on 117 cases. Am J Surg Pathol 23 : 636-650, 1999
PubMed
14) Kohashi K, Oda Y, Yamamoto H et al : SMARCB1/INI1 protein expression in round cell soft tissue sarcomas associated with chromosomal translocations involving EWS : a special reference to SMARCB1/INI1 negative variant extraskeletal myxoid chondrosarcoma. Am J Surg Pathol 32 : 1168-1174, 2008
PubMed
15) Okamoto S, Hisaoka M, Ishida T et al : Extraskeletal myxoid chondrosarcoma : a clinicopathological, immunohistochemical, and molecular analysis of 18 cases. Hum Pathol 32 : 1116-1124, 2001
 
16) Hisaoka M, Okamoto S, Koyama S et al : Microtubule-associated protein-2 and Class III Beta-Tubulin Are Expressed in Extraskeletal Myxoid Chondrosarcoma. Mod Pathol 16 : 453-459, 2003
PubMed
17) Sjogren H, Meis-Kindblom J, Kindblom LG et al : Fusion of the EWS-related gene TAF2N to TEC in extraskeletal myxoid chondrosarcoma. Cancer Res 59 : 5064-5067, 1999
PubMed
18) Sjogren H, Wedell B, Meis-Kindblom JM et al : Fusion of the NH2-terminal domain of the basic helix-loop-helix protein TCF12 to TEC in extraskeletal myxoid chondrosarcoma with translocation t (9 ; 15) (q22 ; q21). Cancer Res 60 : 6832-6835, 2000
PubMed
19) Hisaoka M, Ishida T, Imamura T et al : TFG is a novel fusion partner of NOR1 in extraskeletal myxoid chondrosarcoma. Genes Chromosomes Cancer 40 : 325-328, 2004
PubMed
20) Broehm CJ, Wu J, Gullapalli RR et al : Extraskeletal Myxoid Chondrosarcoma With a t(9 ; 16) (q22 ; p11.2) Resulting in a NR4A3-FUS Fusion. Cancer Genet 207 : 276-280, 2014
 
21) Urbini M, Astolfi A, Pantaleo MA et al : HSPA8 as a novel fusion partner of NR4A3 in extraskeletal myxoid chondrosarcoma. Genes Chromosomes Cancer 56 : 582-586, 2017
PubMed
22) Sjogren H, Meis-Kindblom JM, Orndal C et al : Studies on the molecular pathogenesis of extraskeletal myxoid chondrosarcoma-cytogenetic, molecular genetic, and cDNA microarray analyses. Am J Pathol 162 : 781-792, 2003
PubMed
23) Hisaoka M, Okamoto S, Yokoyama K et al : Coexpression of NOR1 and SIX3 Proteins in Extraskeletal Myxoid Chondrosarcomas Without Detectable NR4A3 Fusion Genes. Cancer Genet Cytogenet 152 : 101-107, 2004
PubMed
24) Oliveira AM, Sebo TJ, McGrory JE et al : Extraskeletal Myxoid Chondrosarcoma : A Clinicopathologic, Immunohistochemical, and Ploidy Analysis of 23 Cases. Mod Pathol 13 : 900-908, 2000
PubMed
25) Agaram NP, Zhang L, Sung YS et al : Extraskeletal myxoid chondrosarcoma with non-EWSR1-NR4A3 variant fusions correlate with rhabdoid phenotype and high-grade morphology. Hum Pathol 45 : 1084-1091, 2014
PubMed
P.172 掲載の参考文献
1) Sesterhenn I, Davis CJ, Mostofi FK : Undifferentiated malignant epithelial tumors involving serosal surfaces of scrotum and abdomen in young males (Abstract). J Urol 137 : 214 A, 1987
 
2) Gerald WL, Rosai J : Case 2. Desmoplastic small cell tumor with divergent differentiation. Pediatr Pathol 9 : 177-183, 1989
PubMed
3) Biegel JA, Conard K, Brooks JJ : Translocation (11 ; 22) (p13 ; q12) : primary change in intraabdominal desmoplastic small round cell tumor. Genes Chromosomes Cancer 7 : 119-121, 1933
 
4) Lae ME, Roche PC, Jin L et al : Desmoplastic small round cell tumor : a clinicopathologic, immunohistochemical, and molecular study of 32 tumors. Am J Surg Pathol 26 : 823-835, 2002
PubMed
5) Ordonez NG : Desmoplastic small round cell tumor : I : a histopathologic study of 39 cases with emphasis on unusual histological patterns. Am J Surg Pathol 22 : 1303-1313, 1998
 
6) Yoshida A, Sekine S, Tsuta K et al : NKX2.2 is a useful immunohistochemical marker for Ewing sarcoma. Am J Surg Pathol 36 : 993-999, 2012
PubMed
7) Hung YP, Lee JP, Bellizzi AM et al : PHOX2B reliably distinguishes neuroblastoma among small round blue cell tumours. Histopathology 71 : 786-794, 2017
PubMed
8) Bulbul A, Fahy BN, Xiu J et al : Desmoplastic Small Round Blue Cell Tumor : A Review of Treatment and Potential Therapeutic Genomic Alterations. Sarcoma 2017 : 1278268, 2017
PubMed
9) Rachfal AW, Luquette MH, Brigstock DR : Expression of connective tissue growth factor (CCN2) in desmoplastic small round cell tumour. J Clin Pathol 57 : 422-425, 2004
PubMed
P.176 掲載の参考文献
1) Beckwith JB, Palmer NF : Histopathology and prognosis of Wilms tumors : results from the First National Wilms' Tumor Study. Cancer 41 : 1937-1948, 1978
PubMed
2) Haas JE, Palmer NF, Weinberg AG et al : Ultrastructure of malignant rhabdoid tumor of the kidney. A distinctive renal tumor of children. Hum Pathol 12 : 646-657, 1981
PubMed
3) Gonzalez-Crussi F, Goldschmidt RA, Hsueh W et al : Infantile sarcoma with intracytoplasmic filamentous inclusions : distinctive tumor of possible histiocytic origin. Cancer 49 : 2365-2375, 1982
PubMed
4) Bonnin JM, Rubinstein LJ, Palmer NF et al : The association of embryonal tumors originating in the kidney and in the brain. A report of seven cases. Cancer 54 : 2137-2146, 1984
 
5) Tsuneyoshi M, Daimaru Y, Hashimoto H et al : Malignant soft tissue neoplasms with the histologic features of renal rhabdoid tumors : an ultrastructural and immunohistochemical study. Hum Pathol 16 : 1235-1242, 1985
PubMed
6) Rorke LB, Packer R, Biegel J : Central nervous system atypical teratoid/rhabdoid tumors of infancy and childhood. J Neurooncol 24 : 21-28, 1995
PubMed
7) Trobaugh-Lotrario AD, Tomlinson GE, Finegold MJ et al : Small cell undifferentiated variant of hepatoblastoma : adverse clinical and molecular features similar to rhabdoid tumors. Pediatr Blood Cancer 52 : 328-334, 2009
PubMed
8) Oda Y, Tsuneyoshi M : Extrarenal rhabdoid tumors of soft tissue : clinicopathological and molecular genetic review and distinction from other soft-tissue sarcomas with rhabdoid features. Pathol Int 56 : 287-295, 2006
PubMed
9) Madigan CE, Armenian SH, Malogolowkin MH et al : Extracranial malignant rhabdoid tumors in childhood : the Childrens Hospital Los Angeles experience. Cancer 110 : 2061-2066, 2007
PubMed
10) Trobaugh-Lotrario AD, Finegold MJ, Feusner JH : Rhabdoid tumors of the liver : rare, aggressive, and poorly responsive to standard cytotoxic chemotherapy. Pediatr Blood Cancer 57 : 423-428, 2011
PubMed
11) Pinto EM, Hamideh D, Bahrami A et al : Malignant rhabdoid tumors originating within and outside the central nervous system are clinically and molecularly heterogeneous. Acta Neuropathol 136 : 315-326, 2018
PubMed
12) Kohashi K, Tanaka Y, Kishimoto H et al : Reclassification of rhabdoid tumor and pediatric undifferentiated/unclassified sarcoma with complete loss of SMARCB1/INI1 protein expression : three subtypes of rhabdoid tumor according to their histological features. Mod Pathol 29 : 1232-1242, 2016
PubMed
13) Hasselblatt M, Gesk S, Oyen F et al : Nonsense mutation and inactivation of SMARCA4 (BRG1) in an atypical teratoid/rhabdoid tumor showing retained SMARCB1 (INI1) expression. Am J Surg Pathol 35 : 933-935, 2011
 
14) Kohashi K, Nakatsura T, Kinoshita Y et al : Glypican 3 expression in tumors with loss of SMARCB1/INI1 protein expression. Hum Pathol 44 : 526-533, 2013
PubMed
15) Yoshida A, Asano N, Kawai A et al : Differential SALL4 immunoexpression in malignant rhabdoid tumours and epithelioid sarcomas. Histopathology 66 : 252-261, 2015
PubMed
16) Kohashi K, Yamada Y, Hotokebuchi Y et al : ERG and SALL4 expressions in SMARCB1/INI1-deficient tumors : a useful tool for distinguishing epithelioid sarcoma from malignant rhabdoid tumor. Hum Pathol 46 : 225-230, 2015
PubMed
17) Biegel JA, Rorke LB, Packer RJ et al : Monosomy 22 in rhabdoid or atypical tumors of the brain. J Neurosurg 73 : 710-714, 1990
 
18) Versteege I, Sevenet N, Lange J et al : Truncating mutations of hSNF5/INI1 in aggressive paediatric cancer. Nature 394 : 203-206, 1998
PubMed
19) Sapi Z, Papp G, Szendroi M et al : Epigenetic regulation of SMARCB1 By miR-206,-381 and-671-5p is evident in a variety of SMARCB1 immunonegative soft tissue sarcomas, while miR-765 appears specific for epithelioid sarcoma. A miRNA study of 223 soft tissue sarcomas. Genes Chromosomes Cancer 55 : 786-802, 2016
 
20) Schaefer IM, Dong F, Garcia EP et al : Recurrent SMARCB1 Inactivation in Epithelioid Malignant Peripheral Nerve Sheath Tumors. Am J Surg Pathol 43 : 835-843, 2019
PubMed
21) Asano N, Yoshida A, Ichikawa H et al : Immunohistochemistry for trimethylated H3K27 in the diagnosis of malignant peripheral nerve sheath tumours. Histopathology 70 : 385-393, 2017
 
22) Hollmann TJ, Hornick JL : INI1-Deficient Tumors : Diagnostic Features and Molecular Genetics. Am J Surg Pathol 35 : e47-e63, 2011
PubMed
23) Kohashi K, Oda Y, Yamamoto H et al : Reduced expression of SMARCB1/INI1 protein in synovial sarcoma. Mod Pathol 23 : 981-990, 2010
PubMed
24) Kadoch C, Crabtree GR : Reversible Disruption of mSWI/SNF (BAF) Complexes by the SS18-SSX Oncogenic Fusion in Synovial Sarcoma. Cell 153 : 71-85, 2013
PubMed
25) Ito J, Asano N, Kawai A et al : The diagnostic utility of reduced immunohistochemical expression of SMARCB1 in synovial sarcomas : a validation study. Hum Pathol 47 : 32-37, 2016
PubMed
26) Hung YP, Fletcher CD, Hornick JL : Evaluation of ETV4 and WT1 expression in CIC-rearranged sarcomas and histologic mimics. Mod Pathol 29 : 1324-1334, 2016
PubMed
P.182 掲載の参考文献
1) Folpe AL, Mentzel T, Lehr HA et al : Perivascular epithelioid cell neoplasms of soft tissue and gynecologic origin : a clinicopathologic study of 26 cases and review of the literature. Am J Surg Pathol 29 : 1558-1575, 2005
PubMed
2) Rao Q, Cheng L, Xia QY et al : Cathepsin K expression in a wide spectrum of perivascular epithelioid cell neoplasms (PEComas) : a clinicopathological study emphasizing extrarenal PEComas. Histopathology 62 : 642-650, 2013
 
3) Agaram NP, Sung YS, Zhang L et al : Dichotomy of Genetic Abnormalities in PEComas With Therapeutic Implications. Am J Surg Pathol 39 : 813-825, 2015
PubMed
4) Argani P, Aulmann S, Illei PB et al : A distinctive subset of PEComas harbors TFE3 gene fusions. Am J Surg Pathol 34 : 1395-1406, 2010
PubMed
5) Maloney N, Giannikou K, Lefferts J et al : Expanding the histomorphologic spectrum of TFE3-rearranged perivascular epithelioid cell tumors. Hum Pathol 82 : 125-130, 2018
PubMed
6) Matsuyama A, Hisaoka M, Ichikawa K et al : Sclerosing variant of epithelioid angiomyolipoma. Pathol Int 58 : 306-310, 2008
PubMed
7) Hornick JL, Fletcher CD : Sclerosing PEComa : clinicopathologic analysis of a distinctive variant with a predilection for the retroperitoneum. Am J Surg Pathol 32 : 493-501, 2008
PubMed
8) Argani P, Zhong M, Reuter VE et al : TFE3-Fusion Variant Analysis Defines Specific Clinicopathologic Associations Among Xp11 Translocation Cancers. Am J Surg Pathol 40 : 723-737, 2016
PubMed
9) Malinowska I, Kwiatkowski DJ, Weiss S et al : Perivascular epithelioid cell tumors (PEComas) harboring TFE3 gene rearrangements lack the TSC2 alterations characteristic of conventional PEComas : further evidence for a biological distinction. Am J Surg Pathol 36 : 783-784, 2012
PubMed
10) Argani P, Zhang L, Sung YS et al : A novel RBMX-TFE3 gene fusion in a highly aggressive pediatric renal perivascular epithelioid cell tumor. Genes Chromosomes Cancer, 2019
 
11) Wang XT, Xia QY, Ni H et al : SFPQ/PSF-TFE3 renal cell carcinoma : a clinicopathologic study emphasizing extended morphology and reviewing the differences between SFPQ-TFE3 RCC and the corresponding mesenchymal neoplasm despite an identical gene fusion. Hum Pathol 63 : 190-200, 2017
PubMed
P.186 掲載の参考文献
1) WHO Classification of Tumours. Soft Tissue and Bone Tumours (5th ed), IARC press, Lyon, 2020
 
2) Gladdy RA, Qin LX, Moraco N et al : Do radiation-associated soft tissue sarcomas have the same prognosis as sporadic soft tissue sarcomas? J Clin Oncol 28 : 2064-2069, 2010
PubMed
3) Goldblum JR, Folpe AL, Weiss SW : Enzinger and Weiss's Soft Tissue Tumors (7th ed), Elsevier, Philadelphia, 2020, pp452-475
 
4) Roland CL, May CD, Watson KL et al : Analysis of clinical and molecular factors impacting oncologic outcomes in undifferentiated pleomorphic sarcoma. Ann Surg Oncol 23 : 2220-2228, 2016
PubMed
5) Macpherson RE, Pratap S, Tyrrell H et al : Retrospective audit of 957 consecutive 18F-FDG PET-CT scans compared to CT and MRI in 493 patients with different histological subtypes of bone and soft tissue sarcoma. Clin Sarcoma Res 8 : 9, 2018
 
6) Sbaraglia M, Righi A, Gambarotti M et al : Ewing sarcoma and Ewing-like tumors. Virchows Arch 476 : 109-119, 2020
PubMed
7) Lewin J, Garg S, Lau BY et al : Identifying actionable variants using next generation sequencing in patients with a historical diagnosis of undifferentiated pleomorphic sarcoma. Int J Cancer 142 : 57-65, 2018
PubMed
8) Hofvander J, Tayebwa J, Nilsson J et al : Recurrent PRDM10 gene fusions in undifferentiated pleomorphic sarcoma. Clin Cancer Res 21 : 864-869, 2015
PubMed
9) Sholl LM, Barletta JA, Hornick JL : Radiation-associated neoplasia : clinical, pathological and genomic correlates. Histopathology 70 : 70-80, 2017
PubMed
P.191 掲載の参考文献
1) Diaz-Perez JA, Nielsen GP, Antonescu C et al : EWSR1/FUS-NFATc2 rearranged round cell sarcoma : clinicopathological series of 4 cases and literature review. Hum Pathol, 2019
PubMed
2) Yoshida K, Machado I, Motoi T et al : NKX3-1 Is a Useful Immunohistochemical Marker of EWSR1-NFATC2 Sarcoma and Mesenchymal Chondrosarcoma. Am J Surg Pathol 44 : 719-728, 2020
PubMed
3) Cohen JN, Sabnis AJ, Krings G et al : EWSR1-NFATC2 gene fusion in a soft tissue tumor with epithelioid round cell morphology and abundant stroma : a case report and review of the literature. Hum Pathol 81 : 281-290, 2018
 
4) Szuhai K, IJszenga M, de Jong D et al : The NFATc2 Gene Is Involved in a Novel Cloned Translocation in a Ewing Sarcoma Variant That Couples Its Function in Immunology to Oncology. Clin Cancer Res 15 : 2259-2268, 2009
 
5) Wang GY, Thomas DG, Davis JL et al : EWSR1-NFATC2 Translocation-associated Sarcoma Clinicopathologic Findings in a Rare Aggressive Primary Bone or Soft Tissue Tumor. Am J Surg Pathol 43 : 1112-1122, 2019
PubMed
6) Charville GW, Wang WL, Ingram DR et al : EWSR1 fusion proteins mediate PAX7 expression in Ewing sarcoma. Mod Pathol 30 : 1312-1320, 2017
PubMed
7) Szuhai K, IJszenga M, Tanke HJ et al : Detection and molecular cytogenetic characterization of a novel ring chromosome in a histological variant of Ewing sarcoma. Cancer Genet Cytogenet 172 : 12-22, 2007
 
8) Watson S, Perrin V, Guillemot D et al : Transcriptomic definition of molecular subgroups of small round cell sarcomas. J Pathol 245 : 29-40, 2018
PubMed
9) Bridge JA, Sumegi J, Druta M et al : Clinical, pathological, and genomic features of EWSR1-PATZ1 fusion sarcoma. Mod Pathol 32 : 1593-1604, 2019
PubMed
10) Chougule A, Taylor MS, Nardi V et al : Spindle and Round Cell Sarcoma With EWSR1-PATZ1 Gene Fusion : A Sarcoma With Polyphenotypic Differentiation. Am J Surg Pathol 43 : 220-228, 2019
PubMed
11) Siegfried A, Rousseau A, Maurage CA et al : EWSR1-PATZ1 gene fusion may define a new glioneuronal tumor entity. Brain Pathol 29 : 53-62, 2019
PubMed
P.196 掲載の参考文献
1) Antonescu CR, Owosho AA, Zhang L et al : Sarcomas With CIC-rearrangements Are a Distinct Pathologic Entity With Aggressive Outcome : A Clinicopathologic and Molecular Study of 115 Cases. Am J Surg Pathol 41 : 941-949, 2017
PubMed
2) Yoshida A, Goto K, Kodaira M et al : CIC-rearranged Sarcomas : A Study of 20 Cases and Comparisons With Ewing Sarcomas. Am J Surg Pathol 40 : 313-323, 2016
PubMed
3) Sturm D, Orr BA, Toprak UH et al : New Brain Tumor Entities Emerge from Molecular Classification of CNS-PNETs. Cell 164 : 1060-1072, 2016
PubMed
4) Gambarotti M, Benini S, Gamberi G et al : CIC-DUX4 fusion-positive round-cell sarcomas of soft tissue and bone : a single-institution morphological and molecular analysis of seven cases. Histopathology 69 : 624-634, 2016
 
5) Italiano A, Sung YS, Zhang L et al : High prevalence of CIC fusion with double-homeobox (DUX4) transcription factors in EWSR1-negative undifferentiated small blue round cell sarcomas. Genes Chromosomes Cancer 51 : 207-218, 2012
PubMed
6) Smith SC, Buehler D, Choi EY et al : CIC-DUX sarcomas demonstrate frequent MYC amplification and ETS-family transcription factor expression. Mod Pathol 28 : 57-68, 2015
PubMed
7) Yamada Y, Kuda M, Kohashi K et al : Histological and immunohistochemical characteristics of undifferentiated small round cell sarcomas associated with CIC-DUX4 and BCOR-CCNB3 fusion genes. Virchows Arch 470 : 373-380, 2017
PubMed
8) Le Loarer F, Pissaloux D, Watson S et al : Clinicopathologic Features of CIC-NUTM1 Sarcomas, a New Molecular Variant of the Family of CIC-Fused Sarcomas. Am J Surg Pathol 43 : 268-276, 2019
PubMed
9) Sugita S, Arai Y, Aoyama T et al : NUTM2A-CIC fusion small round cell sarcoma : A genetically distinct variant of CIC-rearranged sarcoma. Hum Pathol 65 : 225-230, 2017
PubMed
10) Sugita S, Arai Y, Tonooka A et al : A Novel CIC-FOXO4 Gene Fusion in Undifferentiated Small Round Cell Sarcoma : A Genetically Distinct Variant of Ewing-like Sarcoma. Am J Surg Pathol 38 : 1571-1576, 2014
PubMed
11) Huang SC, Zhang L, Sung YS et al : Recurrent CIC Gene Abnormalities in Angiosarcomas : A Molecular Study of 120 Cases With Concurrent Investigation of PLCG1, KDR, MYC, and FLT4 Gene Alterations. Am J Surg Pathol 40 : 645-655, 2016
PubMed
12) Hung YP, Fletcher CD, Hornick JL : Evaluation of ETV4 and WT1 expression in CIC-rearranged sarcomas and histologic mimics. Mod Pathol 29 : 1324-1334, 2016
PubMed
13) Le Guellec S, Velasco V, Perot G et al : ETV4 is a useful marker for the diagnosis of CIC-rearranged undifferentiated round-cell sarcomas : a study of 127 cases including mimicking lesions. Mod Pathol 29 : 1523-1531, 2016
 
14) Specht K, Sung YS, Zhang L et al : Distinct transcriptional signature and immunoprofile of CIC-DUX4 fusion-positive round cell tumors compared to EWSR1-rearranged Ewing sarcomas : further evidence toward distinct pathologic entities. Genes Chromosomes Cancer 53 : 622-633, 2014
PubMed
15) Yoshida A, Arai Y, Kobayashi E et al : CIC break-apart fluorescence in-situ hybridization misses a subset of CIC-DUX4 sarcomas : a clinicopathological and molecular study. Histopathology 71 : 461-469, 2017
PubMed
16) Kawamura-Saito M, Yamazaki Y, Kaneko K et al : Fusion between CIC and DUX4 up-regulates PEA3 family genes in Ewing-like sarcomas with t (4 ; 19) (q35 ; q13) translocation. Hum Mol Genet 15 : 2125-2137, 2006
 
17) Kao YC, Sung YS, Chen CL et al : ETV transcriptional upregulation is more reliable than RNA sequencing algorithms and FISH in diagnosing round cell sarcomas with CIC gene rearrangements. Genes Chromosomes Cancer 56 : 501-510, 2017
PubMed
18) Yoshimoto T, Tanaka M, Homme M et al : CIC-DUX4 Induces Small Round Cell Sarcomas Distinct from Ewing Sarcoma. Cancer Res 77 : 2927-2937, 2017
PubMed
P.201 掲載の参考文献
1) Pierron G, Tirode F, Lucchesi C et al : A new subtype of bone sarcoma defined by BCOR-CCNB3 gene fusion. Nat Genet 44 : 461-466, 2012
 
2) Puls F, Niblett A, Marland G et al : BCOR-CCNB3 (Ewing-like) sarcoma : a clinicopathologic analysis of 10 cases, in comparison with conventional Ewing sarcoma. Am J Surg Pathol 38 : 1307-1318, 2014
PubMed
3) Matsuyama A, Shiba E, Umekita Y et al : Clinicopathologic Diversity of Undif ferentiated Sarcoma With BCOR-CCNB3 Fusion : Analysis of 11 Cases With a Reappraisal of the Utility of Immunohistochemistry for BCOR and CCNB3. Am J Surg Pathol 41 : 1713-1721, 2017
 
4) Yoshida A, Arai Y, Hama N et al : Expanding the clinicopathologic and molecular spectrum of BCOR-associated sarcomas in adults. Histopathology 76 : 509-520, 2020
PubMed
5) Specht K, Zhang L, Sung YS et al : Novel BCOR-MAML3 and ZC3H7B-BCOR Gene Fusions in Undifferentiated Small Blue Round Cell Sarcomas. Am J Surg Pathol 40 : 433-442, 2016
PubMed
6) Kao YC, Owosho AA, Sung YS et al : BCOR-CCNB3 Fusion Positive Sarcomas : A Clinicopathologic and Molecular Analysis of 36 Cases With Comparison to Morphologic Spectrum and Clinical Behavior of Other Round Cell Sarcomas. Am J Surg Pathol 42 : 604-615, 2018
PubMed
7) Wong MK, Ng CCY, Kuick CH et al : Clear cell sarcomas of the kidney are characterised by BCOR gene abnormalities, including exon 15 internal tandem duplications and BCOR-CCNB3 gene fusion. Histopathology 72 : 320-329, 2018
PubMed
8) Antonescu CR, Sung YS, Chen CL et al : Novel ZC3H7B-BCOR, MEAF6-PHF1, and EPC1-PHF1 fusions in ossifying fibromyxoid tumors--molecular characterization shows genetic overlap with endometrial stromal sarcoma. Genes Chromosomes Cancer 53 : 183-193, 2014
PubMed
9) Lewis N, Soslow RA, Delair DF et al : ZC3H7B-BCOR high-grade endometrial stromal sarcomas : a report of 17 cases of a newly defined entity. Mod Pathol 31 : 674-684, 2018
PubMed
10) Kao YC, Sung YS, Zhang L et al : Recurrent BCOR Internal Tandem Duplication and YWHAE-NUTM2B Fusions in Soft Tissue Undifferentiated Round Cell Sarcoma of Infancy : Overlapping Genetic Features With Clear Cell Sarcoma of Kidney. Am J Surg Pathol 40 : 1009-1020, 2016
PubMed
11) Kao YC, Sung YS, Zhang L et al : BCOR Overexpression Is a Highly Sensitive Marker in Round Cell Sarcomas With BCOR Genetic Abnormalities. Am J Surg Pathol 40 : 1670-1678, 2016
PubMed
12) Santiago T, Clay MR, Allen SJ et al : Recurrent BCOR internal tandem duplication and BCOR or BCL6 expression distinguish primitive myxoid mesenchymal tumor of infancy from congenital infantile fibrosarcoma. Mod Pathol 30 : 884-891, 2017
 
13) Alaggio R, Ninfo V, Rosolen A et al : Primitive myxoid mesenchymal tumor of infancy : a clinicopathologic report of 6 cases. Am J Surg Pathol 30 : 388-394, 2006
PubMed

第3部 鑑別ポイント

P.211 掲載の参考文献
1) Baranov E, McBride MJ, Bellizzi AM et al : A Novel SS18-SSX Fusion-specific Antibody for the Diagnosis of Synovial Sarcoma. Am J Surg Pathol 44 : 922-933, 2020
 
2) Asano N, Yoshida A, Ichikawa H et al : Immunohistochemistry for trimethylated H3K27 in the diagnosis of malignant peripheral nerve sheath tumours. Histopathology 70 : 385-393, 2017
 
3) Yoshida A, Tsuta K, Ohno M et al : STAT6 immunohistochemistry is helpful in the diagnosis of solitary fibrous tumors. Am J Surg Pathol 38 : 552-559, 2014
PubMed
4) Nascimento AF, Fletcher CD : Spindle cell rhabdomyosarcoma in adults. Am J Surg Pathol 29 : 1106-1113, 2005
PubMed
5) Pekmezci M, Reuss DE, Hirbe AC et al : Morphologic and immunohistochemical features of malignant peripheral nerve sheath tumors and cellular schwannomas. Mod Pathol 28 : 187-200, 2015
PubMed
6) Chung L, Lau SK, Jiang Z et al : Overlapping features between dedifferentiated liposarcoma and undifferentiated high-grade pleomorphic sarcoma. Am J Surg Pathol 33 : 1594-1600, 2009
 
7) Le Guellec S, Chibon F, Ouali M et al : Are peripheral purely undifferentiated pleomorphic sarcomas with MDM2 amplification dedifferentiated liposarcomas? Am J Surg Pathol 38 : 293-304, 2014
PubMed
8) Agaimy A, Specht K, Stoehr R et al : Metastatic Malignan Melanoma With Complete Loss of Differentiation Markers (Undifferentiated/Dedifferentiated Melanoma) : Analysis of 14 Patients Emphasizing Phenotypic Plasticity and the Value of Molecular Testing as Surrogate Diagnostic Marker. Am J Surg Pathol 40 : 181-191, 2016
 
9) Yamazaki F, Nakatani F, Asano N et al : Novel NTRK3 Fusions in Fibrosarcomas of Adults. Am J Surg Pathol 43 : 523-530, 2019
PubMed
P.228 掲載の参考文献
1) Meis-Kindblom JM, Stenman G, Kindblom LG : Differential diagnosis of small round cell tumors. Semin Diagn Pathol 13 : 213-241, 1996
PubMed
2) 牛込新一郎 : 小円形細胞腫瘍. 取り扱い規約に沿った腫瘍鑑別診断アトラス軟部, 文光堂, 1993, pp151-164
 
3) Bridge JA (ed) : Undifferentiated small round cell sarcomas of bone and soft tissue. in WHO Classification of Tumours, Soft tissue and Bone Tumours (5th ed), IARC, Lyon, 2020, pp321-336
 
4) Ewing J : Diffuse endothelioma of bone. Proc NY Pathol Soc 21 : 17-24, 1921
 
5) Angervall L, Enzinger FM : Extraskeletal neoplasm resembling Ewing's sarcoma. Cancer 36 : 240-251, 1975
PubMed
6) Stout AP : Tumor of the ulnar nerve. Proc NY Pathol Soc 18 : 2-12, 1918
 
7) Askin FB, Rosai J, Sibley RK et al : Malignant small cell tumor of the thoracopulmonary region in childhood. a distinctive clinicopathologic entity of uncertain histogenesis. Cancer 43 : 2438-2451, 1979
PubMed
8) Delattre O, Zucman J, Melot T et al : The Ewing family of tumors. a subgroup of small-round-cell tumors defined by specific chimeric transcripts. N Engl J Med 331 : 294-299, 1994
PubMed
9) Folpe AL, Goldblum JR, Rubin BP et al : Morphologic and immunophenotypic diversity in Ewing family tumors : a study of 66 genetically confirmed cases. Am J Surg Pathol 29 : 1025-1033, 2005
PubMed
10) 大喜多肇, 秦順一 : Ewing肉腫ファミリー腫瘍の臨床病理. 病理と臨床 27 : 151-155, 2009
Medical*Online
11) 石田剛, 大喜多肇, 長谷川匡他 : Ewing肉腫の病理診断上の問題点. 日整会誌 84 : 1126-1131, 2010
Medical*Online
12) Hisaoka M, Hashimoto H, Murao T : Peripheral primitive neuroectodermal tumour with ganglioneuroma-like areas arising in the cauda equina. Virchows Arch 431 : 365-369, 1997
PubMed
13) Bridge JA, Fidler ME, Neff JR et al : Adamantinoma-like Ewing's sarcoma : genomic confirmation, phenotypic drift. Am J Surg Pathol 23 : 159-165, 1999
 
14) Oda Y, Kinoshita Y, Tamiya S et al : Extraskeletal primitive neuroectodermal tumour with massive osteo-cartilaginous metaplasia. Histopathology 36 : 188-191, 2000
PubMed
15) Yoshida A, Sekine S, Tsuta K et al : NKX2.2 is a Useful Immunohistochemical Marker for Ewing Sarcoma. Am J Surg Pathol 36 : 993-999, 2012
PubMed
16) Toki S, Wakai S, Sekimizu M et al : PAX7 immunohistochemical evaluation of Ewing sarcoma and other small round cell tumours. Histopathology 73 : 645-652, 2018
PubMed
17) Bridge RS, Rajaram V, Dehner LP et al : Molecular diagnosis of Ewing sarcoma/primitive neuroectodermal tumor in routinely processed tissue : a comparison of two FISH strategies and RT-PCR in malignant round cell tumors. Mod Pathol 19 : 1-8, 2006
 
18) Machado I, Noguera R, Pellin A et al : Molecular diagnosis of Ewing sarcoma family of tumors : a comparative analysis of 560 cases with FISH and RT-PCR. Diagn Mol Pathol 18 : 189-199, 2009
PubMed
19) 石田剛 : Ewing-like Adamantinoma. 骨腫瘍の病理, 文光堂, 2012, pp343-345
 
20) Yoshida K, Machado I, Motoi T et al : NKX3-1 is a useful immunohistochemical marker of EWSR1-NFATC2 sarcoma and mesenchymal chondrosarcoma. Am J Surg Pathol 44 : 719-728, 2020
PubMed
21) Richkind KE, Romansky SG, Finklestein JZ : t (4 ; 19) (q35 ; q13.1) : A recurrent change in primitive mesenchymal tumors? Cancer Genet Cytogenet 87 : 71-74, 1996
 
22) Kawamura-Saito M, Yamazaki Y, Kaneko K et al : Fusion between CIC and DUX4 up-regulates PEA3 family genes in Ewing-like sarcomas with t (4 ; 19) (q35 ; q13) translocation. Hum Mol Genet 15 : 2125-2137, 2006
 
23) Italiano A, Sung YS, Zhang L et al : High prevalence of CIC fusion with double-homeobox (DUX4) transcription factors in EWSR1-negative undifferentiated small blue round cell sarcomas. Genes Chromosomes Cancer 51 : 207-218, 2012
PubMed
24) Sugita S, Arai Y, Tonooka A et al : A Novel CIC-FOXO4 Gene Fusion in Undifferentiated Small Round Cell Sarcoma : a genetically distinct variant of Ewing-like sarcoma. Am J Surg Pathol 38 : 1571-1576, 2014
PubMed
25) Le Loarer F, Pissaloux D, Watson S et al : Clinicopathologic Features of CIC-NUTM1 Sarcomas, a New Molecular Variant of the Family of CIC-Fused Sarcomas. Am J Surg Pathol 43 : 268-276, 2019
PubMed
26) Antonescu CR, Owosho AA, Zhang L et al : Sarcomas With CIC-rearrangements Are a Distinct Pathologic Entity With Aggressive Outcome. Am J Surg Pathol 41 : 941-949, 2017
PubMed
27) Hung YP, Fletcher CDM, Hornick JL : Evaluation of ETV4 and WT1 expression in CIC-rearranged sarcomas and histologic mimics. Mod Pathol 29 : 1324-1334, 2016
 
28) Siegele B, Roberts J, Black JO et al : DUX4 Immunohistochemistry Is a Highly Sensitive and Specific Marker for CIC-DUX4 Fusion-positive Round Cell Tumor. Am J Surg Pathol 41 : 423-429, 2017
PubMed
29) Yoshida A, Arai Y, Kobayashi E et al : CIC break-apart fluorescence in-situ hybridization misses a subset of CIC-DUX4 sarcomas : a clinicopathological and molecular study. Histopathology 71 : 461-469, 2017
PubMed
30) Pierron G, Tirode F, Lucchesi C et al : A new subtype of bone sarcoma defined by BCOR-CCNB3 gene fusion. Nat Genet 44 : 461-466, 2012
 
31) Specht K, Zhang L, Sung YS et al : Novel BCOR-MAML3 and ZC3H7B-BCOR Gene Fusions in Undifferentiated Small Blue Round Cell Sarcomas. Am J Surg Pathol 40 : 433-442, 2016
PubMed
32) Kao YC, Owosho AA, Sung YS et al : BCOR-CCNB3 Fusion Positive Sarcomas : A Clinicopathologic and Molecular Analysis of 36 Cases with Comparison to Morphologic Spectrum and Clinical Behavior of Other Round Cell Sarcomas. Am J Surg Pathol 42 : 604-615, 2018
PubMed
33) Yoshida A, Arai Y, Hama N et al : Expanding the clinicopathologic and molecular spectrum of BCOR-associated sarcomas in adults. Histopathology 76 : 509-520, 2020
PubMed
34) Kao YC, Sung YS, Zhang L et al : Recurrent BCOR Internal Tandem Duplication and YWHAE-NUTM2B Fusions in Soft Tissue Undifferentiated Round Cell Sarcoma of Infancy. Am J Surg Pathol 40 : 1009-1020, 2016
PubMed
35) Kao YC, Sung YS, Zhang L et al : BCOR Overexpression Is a Highly Sensitive Marker in Round Cell Sarcomas With BCOR Genetic Abnormalities. Am J Surg Pathol 40 : 1670-1678, 2016
PubMed
36) Matsuyama A, Shiba E, Umekita Y et al : Clinicopathologic Diversity of Undif ferentiated Sarcoma With BCOR-CCNB3 Fusion. Analysis of 11 cases with a reappraisal of the utility of immunohistochemistry for BCOR and CCNB3. Am J Surg Pathol 41 : 1713-1721, 2017
 
37) Argani P, Kao YC, Zhang L et al : BCOR Overexpression in Renal Malignant Solitary Fibrous Tumors. A close mimic of clear cell sarcoma of kidney. Am J Surg Pathol 43 : 773-782, 2019
PubMed
38) Sesterhenn I, Davis CJ, Mostofi FK : Undifferentiated malignant epithelial tumors involving serosal surfaces of scrotum and abdomen in young males. J Urol 137 : 214A, 1987
 
39) Gerald WL, Rosai J : Case 2. Desmoplastic small cell tumor with divergent differentiation. Pediatr Pathol 9 : 177-183, 1989
PubMed
40) Gerald WL, Miller HK, Battifora H et al : Intra-abdominal desmoplastic small round-cell tumor. Report of 19 cases of a distinctive type of high-grade polyphenotypic malignancy affecting young individuals. Am J Surg Pathol 15 : 499-513, 1991
 
41) Ordonez NG, el-Naggar AK, Ro JY et al : Intra-abdominal desmoplastic small cell tumor : a light microscopic, immunocytochemical, ultrastructural, and flow cytometric study. Hum Pathol 24 : 850-865, 1993
PubMed
42) Ordonez NG : Desmoplastic small round cell tumor : I : a histopathologic study of 39 cases with emphasis on unusual histological patterns. Am J Surg Pathol 22 : 1303-1313, 1998
 
43) Ordonez NG : Desmoplastic small round cell tumor : II : an ultrastructural and immunohistochemical study with emphasis on new immunohistochemical markers. Am J Surg Pathol 22 : 1314-1327, 1998
 
44) Lae ME, Roche PC, Jin L et al : Desmoplastic small round cell tumor : a clinicopathologic, immunohistochemical, and molecular study of 32 tumors. Am J Surg Pathol 26 : 823-835, 2002
PubMed
45) Gerald WL, Ladanyi M, de Alava E et al : Clinical, pathologic, and molecular spectrum of tumors associated with t (11 ; 22) (p13 ; q12) : desmoplastic small round-cell tumor and its variants. J Clin Oncol 16 : 3028-3036, 1998
 
46) Hill DA, Pfeifer JD, Marley EF et al : WT1 staining reliably differentiates desmoplastic small round cell tumor from Ewing sarcoma/primitive neuroectodermal tumor. An immunohistochemical and molecular diagnostic study. Am J Clin Pathol 114 : 345-353, 2000
PubMed
47) Ladanyi M, Gerald W : Fusion of the EWS and WT1 genes in the desmoplastic small round cell tumor. Cancer Res 54 : 2837-2840, 1994
PubMed
48) Rudzinski ER : Embryonal rhabdomyosarcoma. in WHO Classification of Tumours, Soft tissue and Bone Tumours (5th ed), IARC Press, Lyon, 2019, pp201-204
 
49) Kohashi K, Bode-Lesniewska B : Alveolar thabdomyosarcoma. in WHO Classification of Tumours, Soft tissue and Bone Tumours (5th ed), IARC Press, Lyon, 2019, pp205-208
 
P.236 掲載の参考文献
1) WHO Classification of Tumours Editorial Board : Soft tissue and bone tumours. WHO classification of tumours series (5th ed, vol 3), International Agency for Research on Cancer, Lyon, 2020
 
2) Hornick JL : Subclassification of pleomorphic sarcomas : How and why should we care? Ann Diagn Pathol 37 : 118-124, 2018
PubMed
3) Mentzel T, Calonje E, Fletcher CD : Leiomyosarcoma with prominent osteoclast-like giant cells. Analysis of eight cases closely mimicking the so-called giant cell variant of malignant fibrous histiocytoma. Am J Surg Pathol 18 : 258-265, 1994
PubMed
4) Merchant W, Calonje E, Fletcher CD : Inflammatory leiomyosarcoma : a morphological subgroup within the heterogeneous family of so-called inflammatory malignant fibrous histiocytoma. Histopathology 27 : 525-532, 1995
PubMed
5) Chen E, O'Connell F, Fletcher CD : Dedifferentiated leiomyosarcoma : clinicopathological analysis of 18 cases. Histopathology 59 : 1135-1143, 2011
 
6) Oda Y, Miyajima K, Kawaguchi K et al : Pleomorphic leiomyosarcoma : clinicopathologic and immunohistochemical study with special emphasis on its distinction from ordinary leiomyosarcoma and malignant fibrous histiocytoma. Am J Surg Pathol 25 : 1030-1038, 2001
PubMed
7) Nicolas MM, Tamboli P, Gomez JA et al : Pleomorphic and dedifferentiated leiomyosarcoma : clinicopathologic and immunohistochemical study of 41 cases. Hum Pathol 41 : 663-671, 2010
PubMed
8) Miettinen M : Immunoreactivity for cytokeratin and epithelial membrane antigen in leiomyosarcoma. Arch Pathol Lab Med 112 : 637-640, 1988
PubMed
9) Coindre JM, Terrier P, Guillou L et al : Predictive value of grade for metastasis development in the main histologic types of adult soft tissue sarcomas : a study of 1240 patients from the French Federation of Cancer Centers Sarcoma Group. Cancer 91 : 1914-1926, 2001
PubMed
10) Pisters PW, Leung DH, Woodruff J et al : Analysis of prognostic factors in 1,041 patients with localized soft tissue sarcomas of the extremities. J Clin Oncol 14 : 1679-1689, 1996
PubMed
11) Wang WL, Bones-Valentin RA, Prieto VG et al : Sarcoma metastases to the skin : a clinicopathologic study of 65 patients. Cancer 118 : 2900-2904, 2012
 
12) Noujaim J, Thway K, Jones RL et al : Adult Pleomorphic Rhabdomyosarcoma : A Multicentre Retrospective Study. Anticancer Res 35 : 6213-6217, 2015
PubMed
13) Jagannathan JP, Tirumani SH, Ramaiya NH : Imaging in Soft Tissue Sarcomas : Current Updates. Surg Oncol Clin N Am 25 : 645-675, 2016
 
14) Anderson WJ, Jo VY : Pleomorphic liposarcoma : Updates and current differential diagnosis. Semin Diagn Pathol 36 : 122-128, 2019
PubMed
15) Fletcher CD : Pleomorphic malignant fibrous histiocytoma : fact or fiction? A critical reappraisal based on 159 tumors diagnosed as pleomorphic sarcoma. Am J Surg Pathol 16 : 213-228, 1992
 
16) Weiss SW, Bratthauer GL, Morris PA : Postirradiation malignant fibrous histiocytoma expressing cytokeratin. Implications for the immunodiagnosis of sarcomas. Am J Surg Pathol 12 : 554-558, 1988
PubMed
17) Fletcher CD, Gustafson P, Rydholm A et al : Clinicopathologic re-evaluation of 100 malignant fibrous histiocytomas : prognostic relevance of subclassification. J Clin Oncol 19 : 3045-3050, 2001
 
18) Cancer Genome Atlas Research Network : Comprehensive and Integrated Genomic Characterization of Adult Soft Tissue Sarcomas. Cell 171 : 950-965.e28, 2017
 
19) Derre J, Lagace R, Nicolas A et al : Leiomyosarcomas and most malignant fibrous histiocytomas share very similar comparative genomic hybridization imbalances : an analysis of a series of 27 leiomyosarcomas. Lab Invest 81 : 211-215, 2001
PubMed
20) Carvalho SD, Pissaloux D, Crombe A et al : Pleomorphic Sarcomas : The State of the Art. Surg Pathol Clin 12 : 63-105, 2019
PubMed
21) Dei Tos AP, Doglioni C, Piccinin S et al : Coordinated expression and amplification of the MDM2, CDK4, and HMGI-C genes in atypical lipomatous tumours. J Pathol 190 : 531-536, 2000
 
22) Binh MB, Sastre-Garau X, Guillou L et al : MDM2 and CDK4 immunostainings are useful adjuncts in diagnosing well-differentiated and dedifferentiated liposarcoma subtypes : a comparative analysis of 559 soft tissue neoplasms with genetic data. Am J Surg Pathol 29 : 1340-1347, 2005
PubMed
23) Kang Y, Pekmezci M, Folpe AL et al : Diagnostic utility of SOX10 to distinguish malignant peripheral nerve sheath tumor from synovial sarcoma, including intraneural synovial sarcoma. Mod Pathol 27 : 55-61, 2014
PubMed
24) Schaefer IM, Fletcher CD, Hornick JL : Loss of H3K27 trimethylation distinguishes malignant peripheral nerve sheath tumors from histologic mimics. Mod Pathol 29 : 4-13, 2016
PubMed
25) Pekmezci M, Cuevas-Ocampo AK, Perry A et al : Significance of H3K27me3 loss in the diagnosis of malignant peripheral nerve sheath tumors. Mod Pathol 30 : 1710-1719, 2017
 
26) Prieto-Granada CN, Wiesner T, Messina JL et al : Loss of H3K27me3 Expression Is a Highly Sensitive Marker for Sporadic and Radiation-induced MPNST. Am J Surg Pathol 40 : 479-489, 2016
PubMed
27) Evans HL, Khurana KK, Kemp BL et al : Heterologous elements in the dedifferentiated component of dedifferentiated liposarcoma. Am J Surg Pathol 18 : 1150-1157, 1994
PubMed
P.245 掲載の参考文献
1) Reimann JD, Fletcher CD : Myxoid dermatofibrosarcoma protuberans : a rare variant analyzed in a series of 23 cases. Am J Surg Pathol 31 : 1371-1377, 2007
 
2) Krane JF, Bertoni F, Fletcher CDM : Myxoid synovial sarcoma : an underappreciated morphologic subset. Mod Pathol 12 : 456-462, 1999
 
3) Graadt van Roggen JF, Hogendoorn PCW, Fletcher CDM : Myxoid tumours of soft tissue. Histopathology 35 : 291-312, 1999
 
4) Calonje E, Guerin D, McCormick D et al : Superficial angiomyxoma. Clinicopathologic analysis of a series of distinctive but poorly recognized cutaneous tumors with tendency for recurrence. Am J Surg Pathol 23 : 910-917, 1999
PubMed
5) Sonnex TS : Digital myxoid cysts : A review. Cutis 37 : 89-94, 1986
PubMed
6) Rongioletti F, Rebora A : Cutaneous mucinoses. Microscopic criteria for diagnosis. Am J Dermatopathol 23 : 257-267, 2001
PubMed
7) Fetsch JF, Laskin WB, Hallman JR et al : Neurothekeoma : an analysis of 178 tumors with detailed immunohistochemical data and long-term patient follow-up information. Am J Surg Pathol 31 : 1103-1114, 2007
PubMed
8) Fetsch JF, Laskin WB, Miettinen M : Superficial acral fibromyxoma : a clinicopathologic and immunohistochemical analysis of 37 cases of a distinctive soft tissue tumor with a predilection for the fingers and toes. Hum Pathol 32 : 704-714, 2001
PubMed
9) Zelger BG, Calonje E, Zelger B : Myxoid dermatofibroma. Histopathology 34 : 357-364, 1999
PubMed
10) Tardio JC, Martin-Fragueiro LM : Angiomyxolipoma (vascular myxolipoma) of subcutaneous tissue. Am J Dermatopathol 26 : 222-224, 2004
PubMed
11) Granter S, Nucci M, Fletcher CD : Aggressive angiomyxoma : reappraisal of its relationship to angiomyofibroblastoma in a series of 16 cases. Histopathology 30 : 3-10, 1997
 
12) Miettinen M, Finnell V, Fetsch JF : Ossifying fibromyxoid tumor of soft parts. A clinicopathologic and immunohistochemical study of 104 cases with long-term follow-up and a critical review of the literature. Am J Surg Pathol 32 : 996-1005, 2008
 
13) Marino-Enriquez A, Fletcher CDM : Angiofibroma of soft tissue : clinicopathologic characterization of a distinctive benign fibrovascular neoplasm in a series of 37 cases. Am J Surg Pathol 36 : 500-508, 2012
 
14) Meis-Kindblom JM, Kindblom L-G : Acral myxoinflammatory fibroblastic sarcoma. A low-grade tumor of the hands and feet. Am J Surg Pathol 22 : 911-924, 1998
PubMed
15) Nielsen GP, O'Connell JX, Rosenberg AE : Intramuscular myxoma. A clinicopathologic study of 51 cases with emphasis on hypercellular and hypervascular variants. Am J Surg Pathol 22 : 1222-1227, 1998
PubMed
16) Okamoto S, Hisaoka M, Meis-Kindblom JM et al : Juxtraarticular myxoma and intramuscular myxoma are two distinct entities. Activating Gsα mutation at Arg 201 codon does not occur in juxtra-articular myxoma. Virchows Arch 440 : 12-15, 2002
 
17) Evans HL : Low-grade fibromyxoid sarcoma. A report of 12 cases. Am J Surg Pathol 17 : 595-600, 1993
PubMed
18) Folpe AL, Lane KL, Paull G et al : Low-grade fibromyxoid sarcoma and hyalinizing spindle cell tumor with giant rosettes : a clinicopathologic study of 73 cases supporting their identity and assessing the impact of high-grade areas. Am J Surg Pathol 24 : 1353-1360, 2000
PubMed
19) Rubin BP, Fletcher CD : Myxoid leiomyosarcoma of soft tissue : an underrecognized variant. Am J Surg Pathol 24 : 927-936, 2000
PubMed
20) de Saint Aubain Somerhausen N, Rubin BP, Fletcher CDM : Myxoid solitary fibrous tumor : a study of seven cases with emphasis on differential diagnosis. Mod Pathol 12 : 463-471, 1999
 
P.252 掲載の参考文献
1) Marino-Enriquez A, Wang WL, Roy A et al : Epithelioid inflammatory myofibroblastic sarcoma : An aggressive intra-abdominal variant of inflammatory myofibroblastic tumor with nuclear membrane or perinuclear ALK. Am J Surg Pathol 35 : 135-144, 2011
PubMed
2) Nascimento AF, Bertoni F, Fletcher CDM : Epithelioid variant of myxofibrosarcoma : expanding the clinicomorphologic spectrum of myxofibrosarcoma in a series of 17 cases. Am J Surg Pathol 31 : 99-105, 2007
 
3) Makise N, Yoshida A, Komiyama M et al : Dedifferentiated liposarcoma with epithelioid/epithelial features. Am J Surg Pathol 41 : 1523-1531, 2017
PubMed
4) Miettinen M, Enzinger FM : Epithelioid variant of pleomorphic liposarcoma, a study of 12 cases of a distinctive variant of high-grade liposarcoma. Mod Pathol 12 : 722-728, 1999
PubMed
5) Antonescu CR, Owosho AA, Zhang L et al : Sarcomas with CIC-rearrangements are a distinct pathologic entity with aggressive outcome : A clinicopathologic and molecular study of 115 cases. Am J Surg Pathol 41 : 941-949, 2017
PubMed
6) Meis-Kindblom JM, Kindblom LG : Angiosarcoma of soft tissue. A study of 80 cases. Am J Surg Pathol 22 : 683-697, 1998
 
7) Fletcher CDM, Beham A, Bekir S et al : Epithelioid angiosarcoma of deep soft tissue : A distinctive tumor readily mistaken for an epithelial neoplasm. Am J Surg Pathol 15 : 915-924, 1991
 
8) Bacchi CE, Silva TR, Zambrano E et al : Epithelioid angiosarcoma of the skin. A study of 18 cases with emphasis on its clinicopathologic spectrum and unusual morphologic features. Am J Surg Pathol 34 : 1334-1343, 2010
PubMed
9) Von Hochstetter AR, Meyer VE, Grant JW et al : Epithelioid sarcoma mimicking angiosarcoma : the value of immunohistochemistry in the differential diagnosis. Virchows Arch A Pathol Anat Histopathol 418 : 271-278, 1991
PubMed
10) Hornick JL, Dal Clin P, Fletcher CDM : Loss of INI1 expression is characteristic of both conventional and proximal-type epithelioid sarcoma. Am J Surg Pathol 33 : 542-550, 2009
 
11) Setsu N, Kohashi K, Endo M et al : Inhibin-α and synaptophysin immunoreactivity in synovial sarcoma with granular cell features. Hum Pathol 43 : 850-857, 2012
 
12) Kohashi K, Oda Y, Yamamoto H et al : Highly aggressive behavior of malignant rhabdoid tumor : A special reference to SMARCB1/INI1 gene alterations using molecular genetic analysis including quantitative real-time PCR. J Cancer Res Clin Oncol 133 : 817-824, 2007
PubMed
13) Oda Y, Tsuneyoshi M : Extrarenal rhabdoid tumors of soft tissue : Clinicopathological and molecular genetic review and distinction from other soft-tissue sarcomas with rhabdoid features. Pathol Int 56 : 287-295, 2006
PubMed
14) Kohashi K, Oda Y, Yamamoto H et al : SMARCB1/INI1 protein expression in round cell soft tissue sarcomas associated with chromosomal translocations involving EWS : A special reference to SMARCB1/INI1 negative variant extraskeletal myxoid chondrosarcoma. Am J Surg Pathol 32 : 1168-1174, 2008
PubMed
15) Kohashi K, Izumi T, Oda Y et al : Infrequent SMARCB1/INI1 gene alteration in epithelioid sarcoma : A useful tool in distinguishing epithelioid sarcoma from malignant rhabdoid tumor. Hum Pathol 40 : 349-355, 2009
PubMed
16) Oda Y, Yamamoto H, Kohashi K et al : Soft tissue sarcomas : From a morphological to a molecular biological approach. Pathol Int 67 : 435-446, 2017
PubMed
17) Kohashi K, Oda Y : Oncogenic roles of SMARCB1/INI1 and its deficient tumors. Cancer Sci 108 : 547-552, 2017
PubMed
18) Kohashi K, Oda Y, Yamamoto H et al : Reduced expression of SMARCB1/INI1 protein in synovial sarcoma. Mod Pathol 23 : 981-990, 2010
PubMed
19) Kohashi K, Nakatsura T, Kinoshita Y et al : Glypican 3 expression in tumors with loss of SMARCB1/INI1 protein expression. Hum Pathol 44 : 526-533, 2013
PubMed
20) Kohashi K, Yamada Y, Hotokebuchi Y et al : ERG and SALL4 expressions in SMARCB1/INI1-deficient tumors : a useful tool for distinguishing epithelioid sarcoma from malignant rhabdoid tumor. Hum Pathol 46 : 225-230, 2015
PubMed
P.259 掲載の参考文献
1) Erickson-Johnson MR, Chou MM, Evers BR et al : Nodular fasciitis : a novel model of transient neoplasia induced by MYH9-USP6 gene fusion. Lab Invest 91 : 1427-1433, 2011
PubMed
2) Koizumi H, Mikami M, Doi M et al : Clonality analysis of nodular fasciitis by HUMARA-methylation-specific PCR. Histopathology 47 : 320-321, 2005
PubMed
3) Donner LR, Silva T, Dobin SM : Clonal rearrangement of 15p11.2, 16p11.2, and 16p13.3 in a case of nodular fasciitis : additional evidence favoring nodular fasciitis as a benign neoplasm and not a reactive tumefaction. Cancer Genet Cytogenet 139 : 138-140, 2002
 
4) Shimizu S, Hashimoto H, Enjoji M : Nodular fasciitis : an analysis of 250 patients. Pathology 16 : 161-166, 1984
PubMed
5) Lu Y, He X, Qiu Y et al : Novel CTNNB1-USP6 fusion in intravascular fasciitis of the large vein identified by next-generation sequencing. Virchows Arch 477 : 455-459, 2020
PubMed
6) Patchefsky AS, Enzinger FM : Intravascular fasciitis : a report of 17 cases. Am J Surg Pathol 5 : 29-36, 1981
PubMed
7) Paulson VA, Stojanov IA, Wasman JK et al : Recurrent and novel USP6 fusions in cranial fasciitis identified by targeted RNA sequencing. Mod Pathol 33 : 775-780, 2020
PubMed
8) Barohn RJ, Kasdon DL : Cranial fasciitis : nodular fasciitis of the head. Surg Neurol 13 : 283-285, 1980
PubMed
9) Oshiro Y, Fukuda T, Tsuneyoshi M : Fibrosarcoma versus fibromatoses and cellular nodular fasciitis. A comparative study of their proliferative activity using proliferating cell nuclear antigen, DNA flow cytometry, and p53. Am J Surg Pathol 18 : 712-719, 1994
PubMed
10) Cook JR, Dehner LP, Collins MH et al : Anaplastic lymphoma kinase (ALK) expression in the inflammatory myofibroblastic tumor : a comparative immunohistochemical study. Am J Surg Pathol 25 : 1364-1371, 2001
PubMed
P.265 掲載の参考文献
1) Scheithauer BW, Woodruff JM, Erlandson RA : Atlas of Tumor Pathology, 3rd series, fascicle 24, Tumors of the Peripheral Nervous System, Armed Forces Institute of Pathology, Washington DC, 1999
 
2) Louis DN, Ohgaki H, Wiestler OD et al (ed) : WHO Classification of Tumours of the Central Nervous System (revised 4th ed), IARC Press, Lyon, 2016, pp214-229
 
3) WHO Classification of Tumours Editorial Board : WHO Classification of Tumours (5th ed), Soft Tissue and Bone Tumours. IARC Press, Lyon, 2020, pp226-253
 
4) Casadei GP, Scheithauer BW, Hirose T et al : Cellular schwannoma : a clinicopathologic, DNA flow cytometric, and proliferation marker study of 70 patients. Cancer 75 : 1109-1119, 1995
PubMed
5) Miettinen MM, Antonescu CR, Fletcher CDM et al : Histopathologic evaluation of atypical neurofibromatous tumors and their transformation into malignant peripheral nerve sheath tumor in patients with neurofibromatosis 1-a consensus overview. Hum Pathol 67 : 1-10, 2017
PubMed
6) Hirose T, Scheithauer BW, Sano T : Perineurial malignant peripheral nerve sheath tumor (MPNST) : a clinicopathologic, immunohistochemical, and ultrastructural study of seven cases. Am J Surg Pathol 22 : 1368-1378, 1998
PubMed
7) Fetsch JF, Miettinen M : Sclerosing perineurioma : a clinicopathologic study of 19 cases of a distinctive soft tissue lesion with a predilection for the fingers and palms of young adults. Am J Surg Pathol 21 : 1433-1442, 1997
 
8) Emory TS, Scheithauer BW, Hirose T et al : Intraneural perineurioma. a clonal neoplasm associated with abnormalities of chromosome 22. Am J Clin Pathol 103 : 696-704, 1995
PubMed
9) Cohen JN, Yeh I, Jordan RC et al : Cutaneous non-neural granular cell tumors harbor recurrent ALK gene fusions. Am J Surg Pathol 42 : 1133-1142, 2018
PubMed
10) Fetsch JF, Laskin WB, Miettinen M : Nerve sheath myxoma. A clinicopathologic and immunohistochemical analysis of 57 morphologically distinctive, S-100 protein- and GFAP-positive, myxoid peripheral nerve sheath tumors with a predilection for the extremities and a high local recurrence rate. Am J Surg Pathol 29 : 1615-1624, 2005
 
11) Fetsch JF, Laskin WB, Hallman JR et al : Neurothekeoma : an analysis of 178 tumors with detailed immunohistochemical data and long-term patient follow-up information. Am J Surg Pathol 31 : 1103-1114, 2007
PubMed
12) Sheth S, Li X, Binder S et al : Differential gene expression profiles of neurothekeomas and nerve sheath myxomas by microarray analysis. Mod Pathol 24 : 343-354, 2011
PubMed
13) Hornick JL, Bundock EA, Fletcher CD : Hybrid schwannoma/perineurioma : clinicopathologic analysis of 42 distinctive benign nerve sheath tumors. Am J Surg Pathol 33 : 1554-1561, 2009
PubMed
14) Harder A, Wesemann M, Hagel C et al : Hybrid neurofibroma/schwannoma is overrepresented among schwannomatosis and neurofibromatosis patients. Am J Surg Pathol 36 : 702-709, 2012
PubMed

第4部 臨床との連携

P.271 掲載の参考文献
1) 三上芳喜 : 病理組織・細胞診断報告書の読み方. 笹野公伸, 森谷卓也, 真鍋俊明編 : 臨床医・初期研修医のための病理検査室利用ガイド, 文光堂, 2004, pp83-111
 
2) 三橋智子, 長谷川匡 : 軟部組織. 病理と臨床 (臨増) 26 : 255-260, 2008
 
3) Fletcher CDM, Bridge JA, Pancreas CW et al : World Organization Classification of Tumours of Soft Tissue and Bone IARC Press, Lyon, 2013, p17
 
4) The WHO classification of tumours editorial board (eds) : World Health Organization Classification of Tumours, Soft Tissue and Bone (5th ed), IARC Press, Lyon, 2020, pp10-11
 
5) Lester S : Manual of Surgical Pathology, Churchill Livingstone, Philadelphia, 2001, pp313-318
 
6) Hasegawa T, Yamamoto S, Yokoyama R et al : Prognostic significance of grading and staging systems using MIB-1 score in adult patients with soft tissue sarcoma of the extremities and trunk. Cancer 95 : 843-851, 2002
PubMed
7) Lin X, Davion S, Bertsch EC et al : Federation Nationale des Centers de Lutte Contre le Cancer grading of soft tissue sarcomas on needle core biopsies using surrogate markers. Hum Pathol 56 : 147-154, 2016
PubMed
8) Lesluyes T, Delespaul L, Coindre JM et al : The CINSARC signature as a prognostic marker for clinical outcome in multiple neoplasms. Sci Rep 7 : 5480, 2017
PubMed
9) The WHO classification of tumours editorial board (eds) : World Health Organization Classification of Tumours, Soft Tissue and Bone (5th ed), IARC Press, L yon, 2020, pp216-221
 
P.279 掲載の参考文献
1) American Joint Committee on C, Amin MB : AJCC cancer staging manual (8th ed), Springer, New York, 2017, xvii, pp1024
 
2) Brierley J, Gospodarowicz MK, Wittekind C : TNM classification of malignant tumours, Wiley-Blackwell, New York, 2016
 
3) Enneking WF, Spanier SS, Goodman MA : A system for the surgical staging of musculoskeletal sarcoma. Clin Orthop Relat Res 106-120, 1980
PubMed
4) Hajdu SI, Shiu MH, Brennan MF : The role of the pathologist in the management of soft tissue sarcomas. World J Surg 12 : 326-331, 1988
PubMed
5) Wunder JS, Healey JH, Davis AM et al : A comparison of staging systems for localized extremity soft tissue sarcoma. Cancer 88 : 2721-2730, 2000
PubMed
6) Raney RB, Maurer HM, Anderson JR et al : The Intergroup Rhabdomyosarcoma Study Group (IRSG) : Major Lessons From the IRS-I Through IRS-IV Studies as Background for the Current IRS-V Treatment Protocols. Sarcoma 5 : 9-15, 2001
 
7) 細井創, 土屋邦彦, 杉本徹 : 【小児がん治療の最近の進歩】横紋筋肉腫. 癌と化学療法 34 : 181-186, 2007
 
8) 細野亜古 : 骨軟部腫瘍の薬物治療アップデートEwing肉腫・横紋筋肉腫に対する化学療法. 臨床整形外科 54 : 683-687, 2019
 
9) 森智章, 小林英介, 川井章 : Musculoskeletal Tumor骨・軟部腫瘍 (肉腫) 最近のトピックス 骨軟部腫瘍の病期分類TNM分類第7版から第8版への改訂. 癌と化学療法 46 : 433-436, 2019
 
10) Tanaka K, Ozaki T : New TNM classification (AJCC eighth edition) of bone and soft tissue sarcomas : JCOG Bone and Soft Tissue Tumor Study Group. Jpn J Clin Oncol 49 : 103-107, 2019
 
11) Guillou L, Coindre JM, Bonichon F et al : Comparative study of the National Cancer Institute and French Federation of Cancer Centers Sarcoma Group grading systems in a population of 410 adult patients with soft tissue sarcoma. Clin Oncol 15 : 350-362, 1997
 
12) Ferguson PC, Deheshi BM, Chung P et al : Soft tissue sarcoma presenting with metastatic disease : outcome with primary surgical resection. Cancer 117 : 372-379, 2011
PubMed
13) 森 智章, 小林英介, 上原健敬 他 : 新TNM分類 (UICC8版) は四肢体幹の軟部腫瘍の予後と相関するか. 日本整形外科学会雑誌 92 : S1406, 2018
Medical*Online
14) 日本整形外科学会 骨・軟部腫瘍委員会/国立がん研究センター編 : 全国軟部腫瘍登録一覧表 平成29年度, 2017
 
15) Ramanathan RC, A'Hern R, Fisher C et al : Modified staging system for extremity soft tissue sarcomas. Ann Surg Oncol 6 : 57-69, 1999
PubMed
16) Fisher SB, Chiang YJ, Feig BW et al : Comparative Performance of the 7th and 8th Editions of the American Joint Committee on Cancer Staging Systems for Soft Tissue Sarcoma of the Trunk and Extremities. Ann Surg Oncol 25 : 1126-1132, 2018
PubMed
17) Tanaka K, Tsumura H : Eighth edition of the American Joint Committee on Cancer staging system for soft tissue sarcoma of the trunk and extremity : in search of a better staging system. Ann Transl Med 7 : S11, 2019
PubMed
18) Fisher SB, Chiang YJ, Feig BW et al : An Evaluation of the Eighth Edition of the American Joint Committee on Cancer (AJCC) Staging System for Retroperitoneal Sarcomas Using the National Cancer Data Base (NCDB) : Does Size Matter? Am J Clin Oncol 42 : 160-165, 2019
 
19) Callegaro D, Miceli R, Mariani L et al : Soft tissue sarcoma nomograms and their incorporation into practice. Cancer 123 : 2802-2820, 2017
PubMed
20) Sekimizu M, Ogura K, Yasunaga H et al : Development of nomograms for prognostication of patients with primary soft tissue sarcomas of the trunk and extremity : report from the Bone and Soft Tissue Tumor Registry in Japan. BMC Cancer 19 : 657, 2019
 
21) Bernstein M, Kovar H, Paulussen M et al : Ewing's sarcoma family of tumors : current management. Oncologist 11 : 503-519, 2006
PubMed
22) Adjuvant chemotherapy for localised resectable soft-tissue sarcoma of adults : meta-analysis of individual data. Lancet 350 : 1647-1654, 1997
PubMed
23) Benjamin RS : Evidence for using adjuvant chemotherapy as standard treatment of soft tissue sarcoma. Semin Radiat Oncol 9 : 349-351, 1999
PubMed
24) 日本整形外科学会 骨・軟部腫瘍委員会編 : 整形外科・病理悪性軟部腫瘍取扱い規約, 第3版, 金原出版, 2002
 
25) Kawaguchi N, Ahmed AR, Matsumoto S et al : The concept of curative margin in surgery for bone and soft tissue sarcoma. Clin Orthop Relat Res 165-172, 2004
 
26) 阿江啓介, 松本誠一 : 【骨軟部腫瘍の診断と治療】 (Part3) 臨床 <治療> 新しい切除縁評価とその概念. Bone Joint Nerve 7 : 459-468, 2017
 
27) Novais EN, Demiralp B, Alderete J et al : Do surgical margin and local recurrence influence survival in soft tissue sarcomas? Clin Orthop Relat Res 468 : 3003-3011, 2010
PubMed
28) Rauh J, Klein A, Baur-Melnyk A et al : The role of surgical margins in atypical Lipomatous Tumours of the extremities. BMC Musculoskelet Disord 19 : 152, 2018
 
29) Tanaka K, Mizusawa J, Naka N et al : Ten-year follow-up results of perioperative chemotherapy with doxorubicin and ifosfamide for high-grade soft-tissue sarcoma of the extremities : Japan Clinical Oncology Group study JCOG0304. BMC Cancer 19 : 890, 2019
 
30) Tanaka K, Mizusawa J, Fukuda H et al : Perioperative chemotherapy with ifosfamide and doxorubicin for high-grade soft tissue sarcomas in the extremities (JCOG0304). Jpn J Clin Oncol 45 : 555-561, 2015
PubMed
31) Gronchi A, Ferrari S, Quagliuolo V et al : Histotype-tailored neoadjuvant chemotherapy versus standard chemotherapy in patients with high-risk soft-tissue sarcomas (ISG-STS 1001) : an international, open-label, randomised, controlled, phase 3, multicentre trial. Lancet Oncol 18 : 812-822, 2017
PubMed
32) Judson I, Verweij J, Gelderblom H et al : Doxorubicin alone versus intensified doxorubicin plus ifosfamide for first-line treatment of advanced or metastatic soft-tissue sarcoma : a randomised controlled phase 3 trial. Lancet Oncol 15 : 415-423, 2014
PubMed
33) van der Graaf WTA, Blay JY, Chawla SP et al : Pazopanib for metastatic soft-tissue sarcoma (PALETTE) : a randomised, double-blind, placebo-controlled phase 3 trial. Lancet 379 : 1879-1886, 2012
 
34) Kawai A, Araki N, Sugiura H et al : Trabectedin monotherapy after standard chemotherapy versus best supportive care in patients with advanced, translocation-related sarcoma : a randomised, open-label, phase 2 study. Lancet Oncol 16 : 406-416, 2015
PubMed
35) Schoffski P, Chawla S, Maki RG et al : Eribulin versus dacarbazine in previously treated patients with advanced liposarcoma or leiomyosarcoma : a randomised, open-label, multicentre, phase 3 trial. Lancet 387 : 1629-1637, 2016
 
P.288 掲載の参考文献
1) Van Glabbeke M, van Oosterom AT, Oosterhuis JW et al : Prognostic factors for the outcome of chemotherapy in advanced soft tissue sarcoma : an analysis of 2,185 patients treated with anthracycline-containing first-line regimens-a European Organization for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group Study. J Clin Oncol 17 : 150-157, 1999
 
2) Sleijfer S, Ouali M, van Glabbeke M et al : Prognostic and predictive factors for outcome to first-line ifosfamide-containing chemotherapy for adult patients with advanced soft tissue sarcomas : an exploratory, retrospective analysis on large series from the European Organization for Research and Treatment of Cancer-Soft Tissue and Bone Sarcoma Group (EORTC-STBSG). Eur J Cancer 46 : 72-83, 2010
PubMed
3) Grier HE, Krailo MD, Tarbell NJ et al : Addition of ifosfamide and etoposide to standard chemotherapy for Ewing's sarcoma and primitive neuroectodermal tumor of bone. N Engl J Med 348 : 694-701, 2003
 
4) Arndt CA, Stoner JA, Hawkins DS et al : Vincristine, actinomycin, and cyclophosphamide compared with vincristine, actinomycin, and cyclophosphamide alternating with vincristine, topotecan, and cyclophosphamide for intermediate-risk rhabdomyosarcoma : children's oncology group study D9803. J Clin Oncol 27 : 5182-5188, 2009
 
5) Judson I, Verweij J, Gelderblom H et al : Doxorubicin alone versus intensified doxorubicin plus ifosfamide for first-line treatment of advanced or metastatic soft-tissue sarcoma : a randomized controlled phase 3 trial. Lancet Oncol 15 : 415-423, 2014
PubMed
6) Hensley ML, Blessing JA, Mannel R et al : Fixed-dose rate gemcitabine plus docetaxel as first-line therapy for metastatic uterine leiomyosarcoma : a Gynecologic Oncology Group phase II trial. Gynecol Oncol 109 : 329-334, 2008
PubMed
7) Tanaka K, Mizusawa J, Fukuda H et al : Perioperative chemotherapy with ifosfamide and doxorubicin for high-grade soft tissue sarcomas in the extremities (JCOG0304). Jpn J Clin Oncol 45 : 555-561, 2015
PubMed
8) Penel N, Bui BN, Bay JO et al : Phase II trial of weekly paclitaxel for unresectable angiosarcoma : the ANGIOTAX Study. J Clin Oncol 26 : 5269-5274, 2008
PubMed
9) Schoffski P, Chawla S, Maki RG et al : Eribulin versus dacarbazine in previously treated patients with advanced liposarcoma or leiomyosarcoma : a randomised, open-label, multicentre, phase 3 trial. Lancet 387 : 1629-1637, 2016
 
10) van der Graaf WTA, Blay JY, Chawla SP et al : Pazopanib for metastatic soft-tissue sarcoma (PALETTE) : a randomized, double-blind, placebo-controlled phase 3 trial. Lancet 379 : 1879-1886, 2012
 
11) Donaldson SS, Anderson JR : Rhabdomyosarcoma : many similarities, a few philosophical differences. J Clin Oncol 23 : 2586-2587, 2005
PubMed
12) Raney RB, Anderson JR, Barr FG et al : Rhabdomyosarcoma and undifferentiated sarcoma in the first two decades of life : a selective review of intergroup rhabdomyosarcoma study group experience and rationale for Intergroup Rhabdomyosarcoma Study V. J Pediatr Hematol Oncol 23 : 215-220, 2001
 
13) Williamson D, Missiaglia E, de Reynies A et al : Fusion Gene-Negative Alveolar Rhabdomyosarcoma Is Clinically and Molecularly Indistinguishable From Embryonal Rhabdomyosarcoma. J Clin Oncol 28 : 2151-2158, 2010
PubMed
14) Crist WM, Anderson JR, Meza JL et al : Intergroup rhabdomyosarcoma study-IV : results for patients with nonmetastatic disease. J Clin Oncol 19 : 3091-3102, 2001
 
15) Walterhouse DO, Pappo AS, Meza JL et al : Shorter-Duration Therapy Using Vincristine, Dactinomycin,and Lower-Dose Cyclophosphamide With or Without Radiotherapy for Patients With Newly Diagnosed Low-Risk Rhabdomyosarcoma : A Report From the Soft Tissue Sarcoma Committee of the Children's Oncology Group. J Clin Oncol 32 : 3547-3552, 2014
PubMed
16) Otten J, Flamant F, Rodary C et al : Treatment of rhabdomyosarcoma and other malignant mesenchymal tumours of childhood with ifosfamide+vincristine+dactinomycin (IVA) as front-line therapy (a SIOP study). Cancer Chemother Pharmacol 24 (Suppl 1) : S30, 1989
 
17) Arndt C, Tefft M, Gehan E et al : A feasibility, toxicity, and early response study of etoposide, ifosfamide, and vincristine for the treatment of children with rhabdomyosarcoma : a report from the Intergroup Rhabdomyosarcoma Study (IRS) IV pilot study. J Pediatr Hematol Oncol 19 : 124-129, 1997
 
18) Baker KS, Anderson JR, Link MP et al : Benefit of intensified therapy for patients with local or regional embryonal rhabdomyosarcoma : results from the Intergroup Rhabdomyosarcoma Study IV. J Clin Oncol 18 : 2427-2434, 2000
PubMed
19) Hawkins DS, Chi YY, Anderson JR et al : Addition of Vincristine and Irinotecan to Vincristine, Dactinomycin, and Cyclophosphamide Does Not Improve Outcome for Intermediate-Risk Rhabdomyosarcoma : A Report From the Children's Oncology Group. J Clin Oncol 36 : 2770-2777, 2018
 
20) Breneman JC, Lyden E, Pappo AS et al : Prognostic factors and clinical outcomes in children and adolescents with metastatic rhabdomyosarcoma-a report from the Intergroup Rhabdomyosarcoma Study IV. J Clin Oncol 21 : 78-84, 2003
 
21) Weigel BJ, Lyden E, Anderson JR et al : Intensive Multiagent Therapy, Including Dose-Compressed Cycles of Ifosfamide/Etoposide and Vincristine/Doxorubicin/Cyclophosphamide, Irinotecan, and Radiation, in Patients With High-Risk Rhabdomyosarcoma : A Report From the Children's Oncology Group. J Clin Oncol 34 : 117-122, 2016
 
22) Brennan B, Kirton L, Marec-Berard P et al : Comparison of two chemotherapy regimens in Ewing sarcoma (ES) : Overall and subgroup results of the Euro Ewing 2012 randomized trial (EE2012). J Clin Oncol 38 : 2020 (suppl ; abstr 11500)
 
23) Ladenstein R, Potschger U, Le Deley MC et al : Primary disseminated multifocal Ewing sarcoma : results of the Euro-EWING 99 trial. J Clin Oncol 28 : 3284-3291, 2010
 
24) Zoubek A, Dockhorn-Dworniczak B, Delattre O et al : Does expression of different EWS chimeric transcripts define clinically distinct risk groups of Ewing tumor patients? J Clin Oncol 14 : 1245-1251, 1996
PubMed
25) de Alava E, Kawai A, Healey JH et al : EWS-FLI1 fusion transcript structure is an independent determinant of prognosis in Ewing's sarcoma. J Clin Oncol 16 : 1248-1255, 1998
PubMed
26) Le Deley MC, Delattre O, Schaefer KL et al : Impact of EWS-ETS fusion type on disease progression in Ewing's sarcoma/peripheral primitive neuroectodermal tumor : prospective results from the cooperative Euro-E.W.I.N.G. 99 trial. J Clin Oncol 28 : 1982-1988, 2010
 
27) van Doorninck JA, Ji L, Schaub B et al : Current treatment protocols have eliminated the prognostic advantage of type 1 fusions in Ewing sarcoma : a report from the Children's Oncology Group. J Clin Oncol 28 : 1989-1994, 2010
 
28) McCarter MD, Lewis JJ, Antonescu CR et al : Extraskeletal osteosarcoma : analysis of outcome of a rare neoplasm. Sarcoma 4 : 119-123, 2000
PubMed
29) Rosen G, Marcove RC, Caparros B et al : Primary osteogenic sarcoma : the rationale for preoperative chemotherapy and delayed surgery. Cancer 43 : 2163-2177, 1979
PubMed
30) Goorin AM, Schwartzentruber DJ, Devidas M et al : Presurgical chemotherapy compared with immediate surgery and adjuvant chemotherapy for nonmetastatic osteosarcoma : Pediatric Oncology Group Study POG-8651. J Clin Oncol 21 : 1574-1580, 2003
 
31) Souhami RL, Craft AW, Van der Eijken JW et al : Randomised trial of two regimens of chemotherapy in operable osteosarcoma : a study of the European Osteosarcoma Intergroup. Lancet 350 : 911-917, 1997
PubMed
32) Bramwell VH, Burgers M, Sneath R et al : A comparison of two short intensive adjuvant chemotherapy regimens in operable osteosarcoma of limbs in children and young adults : the first study of the European Osteosarcoma Intergroup. J Clin Oncol 10 : 1579-1591, 1992
 
33) Fuchs N, Bielack SS, Epler D et al : Long-term results of the co-operative German-Austrian-Swiss osteosarcoma study group's protocol COSS-86 of intensive multidrug chemotherapy and surgery for osteosarcoma of the limbs. Ann Oncol 9 : 893-899, 1998
 
34) Smeland S, Muller C, Alvegard TA et al : Scandinavian Sarcoma Group Osteosarcoma Study SSG VIII : prognostic factors for outcome and the role of replacement salvage chemotherapy for poor histological responders. Eur J Cancer 39 : 488-494, 2003
PubMed
35) Winkler K, Beron G, Delling G et al : Neoadjuvant Chemotherapy of Osteosarcoma : Results of a Randomized Cooperative Trial (COSS-82) With Salvage Chemotherapy Based on Histological Tumor Response. J Clin Oncol 6 : 329-337, 1988
PubMed
36) Saeter G, Alvegard TA, Elomaa I et al : Treatment of osteosarcoma of the extremities with the T-10 protocol, with emphasis on the effects of preoperative chemotherapy with single-agent high-dose methotrexate : a Scandinavian Sarcoma Group study. J Clin Oncol 9 : 1766-1775, 1991
 
37) Marina N, Bielack S, Whelan J et al : International Collaboration is Feasible in Trials for Rare Conditions : The EURAMOS Experience. Cancer Treat Res 152 : 339-353, 2009
PubMed
38) Iwamoto Y, Tanaka K, Isu K et al : Multiinstitutional phase II study of neoadjuvant chemotherapy for osteosarcoma (NECO study) in Japan : NECO-93J and NECO-95J. J Orthop Sci 14 : 397-404, 2009
PubMed
39) 日本臨床腫瘍研究グループ : JCOG0905 (http://www.jcog.jp/document/0905.pdf)
 
40) Bramwell VH, Anderson D, Charette ML et al : "Doxorubicin-based chemotherapy for the palliative treatment of adult patients with locally advanced or metastatic soft tissue sarcoma". Cochrane Database Sys Rev 2003 : CD003293, 2003
 
41) Verma S, Younus J, Stys-Norman D et al : Meta-analysis of ifosfamide-based combination chemotherapy in advanced soft tissue sarcoma. Cancer Treat Rev 34 : 339-347, 2008
PubMed
42) Edmonson JH, Ryan LM, Blum RH et al : Randomized comparison of doxorubicin alone versus ifosfamide plus doxorubicin or mitomycin, doxorubicin, and cisplatin against advanced soft tissue sarcomas. J Clin Oncol 11 : 1269-1275, 1993
PubMed
43) Seddon B, Strauss SJ, Whelan J et al : Gemcitabine and docetaxel versus doxorubicin as first-line treatment in previously untreated advanced unresectable or metastatic soft-tissue sarcomas (GeDDiS) : a randomized controlled phase 3 trial. Lancet Oncol 18 : 1397-1410, 2017
PubMed
44) Gottlieb JA, Benjamin RS, Baker LH et al : Role of DTIC (NSC-45388) in the chemotherapy of sarcomas. Cancer Treat Rep 60 : 199-203, 1976
PubMed
45) Patel SR, Gandhi V, Jenkins J et al : Phase II clinical investigation of gemcitabine in advanced soft tissue sarcomas and window evaluation of dose rate on gemcitabine triphosphate accumulation. J Clin Oncol 19 : 3483-3489, 2001
 
46) Maki RG, Wathen JK, Patel SR et al : Randomized phase II study of gemcitabine and docetaxel compared with gemcitabine alone in patients with metastatic soft tissue sarcomas : results of sarcoma alliance for research through collaboration study 002 [corrected]. J Clin Oncol 25 : 2755-2763, 2007
PubMed
47) Gottlieb JA, Baker LH, Quagliana JM et al : Chemotherapy of sarcomas with a combination of adriamycin and dimethyl triazeno imidazole carboxamide. Cancer 30 : 1632-1638, 1972
PubMed
48) Lorigan P, Verweij J, Papai Z et al : Phase III trial of two investigational schedules of ifosfamide compared with standard-dose doxorubicin in advanced or metastatic soft tissue sarcoma : a European Organisation for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group Study. J Clin Oncol 25 : 3144-3150, 2007
PubMed
49) Casali PG, Blay JY et al : Soft tissue sarcomas : ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 21 (Suppl 5) : v198-v203, 2010
 
50) Stuart-Harris RC, Harper PG, Parsons CA et al : Highdose alkylation therapy using ifosfamide infusion with mesna in the treatment of adult advanced soft-tissue sarcoma. Cancer Chemother Pharmacol 11 : 69-72, 1983
PubMed
51) Antman KH, Montella D, Rosenbaum C et al : Phase II trial of ifosfamide with mesna in previously treated metastatic sarcoma. Cancer Treat Rep 69 : 499-504, 1985
PubMed
52) Benjamin RS, Legha SS, Patel SR et al : Single-agent ifosfamide studies in sarcomas of soft tissue and bone : the M. D. Anderson experience. Cancer Chemother Pharmacol 31 (Suppl 2) : S174-179, 1993
 
53) Patel SR, Vadhan-Raj S, Papadopolous N et al : Highdose ifosfamide in bone and soft tissue sarcomas : results of phase II and pilot studies-dose-response and schedule dependence. J Clin Oncol 15 : 2378-2384, 1997
 
54) van Oosterom AT, Mouridsen HT, Nielsen OS et al : Results of randomised studies of the EORTC Soft Tissue and Bone Sarcoma Group (STBSG) with two different ifosfamide regimens in first- and second-line chemotherapy in advanced soft tissue sarcoma patients. Eur J Cancer 38 : 2397-2406, 2002
PubMed
55) Grosso F, Jones RL, Demetri GD et al : Efficacy of trabectedin (ecteinascidin-743) in advanced pretreated myxoid liposarcomas : a retrospective study. Lancet Oncol 8 : 595-602, 2007
PubMed
56) Kuroda M, Ishida T, Takanashi M et al : Oncogenic transformation and inhibition of adipocytic conversion of preadipocytes by TLS/FUS-CHOP type II chimeric protein. Am J Pathol 151 : 735-744, 1997
PubMed
57) Kawai A, Araki N, Sugiura H et al : Trabectedin monotherapy after standard chemotherapy versus best supportive care in patients with advanced, translocation-related sarcoma : a randomised, open-label, phase 2 study. Lancet Oncol 16 : 406-416, 2015
PubMed
58) Pervaiz N, Colterjohn N, Farrokhyar F et al : A systematic meta-analysis of randomized controlled trials of adjuvant chemotherapy for localized resectable soft-tissue sarcoma. Cancer 113 : 573-581, 2008
PubMed
59) Penella JW, Reichardt P, Le Cesne A et al : Adjuvant chemotherapy with doxorubicin, ifosfamide, and lenograstim for resected soft-tissue sarcoma (EORTC 62931) : a multicentre randomised controlled trial. Lancet Oncol 13 : 1045-1054, 2012
 
60) Gronchi A, Palmerini E, Quagliuolo V : Neoadjvant Chemotherapy in High-risk Soft Tissue Sarcomas : Final Results of Randomized Trial From Italian (ISG), Spanish (GEIS), French (FSG), and Polish (PSG) Sarcoma Groups. J Clin Oncol 38 : 2178-2186, 2020
 
61) Gortzak E, Azzarelli A, Buesa J et al : A randomised phase II study on neo-adjuvant chemotherapy for 'highrisk' adult soft-tissue sarcoma. Eur J Cancer 37 : 1096-1103, 2001
 
62) Chawla SP, Tolcher AW, Staddon AP et al : Survival results with AP23573, a novel mTOR inhibitor, in patients (pts) with advanced soft tissue or bone sarcomas : Update of phase II trial. J Clin Oncol 25 : 10076-10076, 2007
 
63) Demetri GD, Chawla SP, Ray-Coquard I et al : Results of an International Randomized Phase III Trial of the Mammalian Target of Rapamycin Inhibitor Ridaforolimus Versus Placebo to Control Metastatic Sarcomas in Patients After Benefit From Prior Chemotherapy. J Clin Oncol 31 : 2485-2492, 2013
PubMed
64) Manara MC, Landuzzi L, Nanni P et al : Preclinical in vivo study of new insulin-like growth factor-I receptorspecific inhibitor in Ewing's sarcoma. Clin Cancer Res 13 : 1322-1330, 2007
 
65) Olmos D, Postel-Vinay S, Molife LR et al : Safety, pharmacokinetics, and preliminary activity of the anti-IGF-1R antibody figitumumab (CP-751, 871) in patients with sarcoma and Ewing's sarcoma : a phase 1 expansion cohort study. Lancet Oncol 11 : 129-135, 2010
PubMed
66) Malempati S, Weigel B, Ingle AM et al : Phase I/II Trial and Pharmacokinetic Study of Cixutumumab in Pediatric Patients With Refractory Solid Tumors and Ewing Sarcoma : A Report From the Children's Oncology Group. J Clin Oncol 30 : 256-262, 2011
 
67) Mangoni M, Sottili M, Salvatore G et al : Soft tissue sarcomas : new opportunity of treatment with PARP inhibitors? Radiol Med 124 : 282-289, 2019
PubMed
68) Grignami G, D'Ambrosio L, Pignochino Y et al : Trabectedin and olaparib in patients with advanced non-resectable bone and soft-tissue sarcomas (TOMAS) : an open-label, phase 1b study from the Italian Sarcoma Group. Lancet Oncol 19 : 1360-1371, 2018
 
P.298 掲載の参考文献
1) 鳴海善文, 中村仁信 : 非イオン性ヨード造影剤およびガドリニウム造影剤の重症副作用および死亡例の頻度調査. 日本医学放射線学会雑誌 65 : 300-301, 2005
 
2) 日本核医学会 : FDG PET, PET/CT診療ガイドライン 2020, 2020
 
3) Erfanian Y, Grueneisen J, Kirchner J et al : Integrated 18F-FDG PET/MRI compared to MRI alone for identification of local recurrences of soft tissue sarcomas : a comparison trial. Eur J Nucl Med Mol Imaging 44 : 1823-1831, 2017
PubMed
4) Chen L, Wu X, Ma X et al : Prognostic value of 18F-FDG PET-CT-based functional parameters in patients with soft tissue sarcoma : A meta-analysis. Medicine (Baltimore) 96 : e5913, 2017
PubMed
5) Kandathil A, Subramaniam RM : PET/Computed Tomography and Precision Medicine : Musculoskeletal Sarcoma. PET Clin 12 : 475-488, 2017
PubMed
6) Kitao T, Shiga T, Hirata K et al : Volume-based parameters on FDG PET may predict the proliferative potential of soft-tissue sarcomas. Ann Nucl Med 33 : 22-31, 2019
PubMed
7) Bradley WG Jr : MR appearance of hemorrhage in the brain. Radiology 189 : 15-26, 1993
PubMed
P.306 掲載の参考文献
1) Delattre O, Zucman J, Plougastel B et al : Gene fusion with an ETS DNA-binding domain caused by chromosome translocation in human tumours. Nature 359 : 162-165, 1992
PubMed
2) The Cancer Genome Atlas Research Network : Comprehensive and integrated genomic characterization of adult soft tissue sarcomas. Cell 171 : 950-965, 2017
 
3) Szuhai K, de Jong D, Leung WY et al : Transactivating mutation of the MYOD1 gene is a frequent event in adult spindle cell rhabdomyosarcoma. J Pathol 232 : 300-307, 2014
PubMed
4) Ueno-Yokohata H, Okita H, Nakasato K et al : Consistent in-frame internal tandem duplications of BCOR characterize clear cell sarcoma of the kidney. Nat Genet 47 : 861-863, 2015
PubMed
5) Tonini G, Boni L, Pession A et al : MYCN oncogene amplification in neuroblastoma is associated with worse prognosis, except in stage 4s : the Italian experience with 295 children. J Clin Oncol 15 : 85-93, 1997
 
6) Seshadri R, Matthews C, Dobrovic A et al : The significance of oncogene amplification in primary breast cancer. Int J Cancer 43 : 270-272, 1989
PubMed
7) Oliner JD, Kinzler KW, Meltzer PS et al : Amplification of a gene encoding a p53-associated protein in human sarcomas. Nature 358 : 80-83, 1992
PubMed
8) Momand J, Zambetti GP, Olson DC et al : The mdm-2 oncogene product forms a complex with the p53 protein and inhibits p53-mediated transactivation. Cell 69 : 1237-1245, 1992
PubMed
9) Nibert M, Heim S : Uterine leiomyoma cytogenetics. Genes Chromosomes Cancer 2 : 3-13, 1990
PubMed
10) Pedeutour F, Forus A, Coindre JM et al : Structure of the supernumerary ring and giant rod chromosomes in adipose tissue tumors. Genes Chromosomes Cancer 24 : 30-41, 1999
PubMed
11) Le Guellec S, Chibon F, Ouali M et al : Are peripheral purely undifferentiated pleomorphic sarcomas with MDM2 amplification dedifferentiated liposarcomas? Am J Surg Pathol 38 : 293-304, 2014
PubMed
12) Italiano A, Bianchini L, Keslair F et al : HMGA2 is the partner of MDM2 in well-differentiated and dedifferentiated liposarcomas whereas CDK4 belongs to a distinct inconsistent amplicon. Int J Cancer 122 : 2233-2241, 2008
PubMed
13) Teramura Y, Tanaka M, Yamazaki Y et al : Identification of novel fusion genes in bone and soft tissue sarcoma and their implication in the generation of a mouse model. Cancers (Basel) 12 : 2345, 2020
 
14) Lee W, Teckie S, Wiesner T et al : PRC2 is recurrently inactivated through EED or SUZ12 loss in malignant peripheral nerve sheath tumors. Nat Genet 46 : 1227-1232, 2014
PubMed
15) Sohier P, Luscan A, Lloyd A et al : Confirmation of mutation landscape of NF1-associated malignant peripheral nerve sheath tumors. Genes Chromosomes Cancer 56 : 421-426, 2017
PubMed
16) Dagrada GP, Spagnuolo RD, Mauro V et al : Solitary fibrous tumors : loss of chimeric protein expression and genomic instability mark dedifferentiation. Mod Pathol 28 : 1074-1083, 2015
PubMed
17) Mohammad HP, Barbash O, Creasy CL : Targeting epigenetic modifications in cancer therapy : erasing the roadmap to cancer. Nat Med 25 : 403-418, 2019
PubMed
18) Burslem GM, Crews CM : Proteolysis-targeting chimeras as therapeutics and tools for biological discovery. Cell 181 : 102-114, 2020
PubMed
P.315 掲載の参考文献
1) 日本整形外科学会 骨・軟部腫瘍委員会編 : 整形外科・病理悪性軟部腫瘍取扱い規約, 第2版, 金原出版, 1989
 
2) 日本整形外科学会 骨・軟部腫瘍委員会編 : 骨・軟部肉腫切除縁評価法, 金原出版, 1989
 
3) 阿江啓介, 松本誠一, 下地尚他 : 切除縁評価法の改正にむけて-バリア概念の検証. 日本整形外科学会雑誌 86 : 567-574, 2014
 
4) 松本誠一, 川口智義, 真鍋淳他 : 骨軟部肉腫の手術療法. 癌と化学療法 31 : 1314-1318, 2004
Medical*Online
5) Ueda T, Naka N, Araki N et al : Validation of radiographic response evaluation criteria of preoperative chemotherapy for bone and soft tissue sarcomas : Japanese Orthopaedic Association Committee on Musculoskeletal Tumors Cooperative Study. J Orthop Sci 13 : 304-312, 2008
PubMed
6) Spurrell EL, Fisher C, Thomas JM et al : Prognostic factors in advanced synovial sarcoma : an analysis of 104 patients treated at the Royal Marsden Hospital. Ann Oncol 16 : 437-444, 2005
 
7) 五嶋孝博, 大隈和威, 小倉浩一他 : 骨軟部肉腫における組織型からみた化学療法の適応. 癌と化学療法 36 : 199-203, 2009
 
8) 遠藤誠 : 骨・軟部腫瘍, III. 脂肪肉腫に対する薬物療法. 癌と化学療法 37 : 434-438, 2010
 
9) 日本整形外科学会・日本病理学会編 : 整形外科・病理悪性骨腫瘍取扱い規約, 第4版, 金原出版, 2015
 
10) 蛭田啓之, 町並陸生, 神田浩明他 : 骨肉腫の術前化学療法組織学的効果判定と問題点. 日整会誌 84 : 1120-1125, 2010
Medical*Online
11) 小田義直, 野島孝之, 廣瀬隆則 他 : 日本臨床腫瘍研究グループ骨軟部腫瘍グループ2020年度第1回班会議資料
 
12) Kawaguchi N, Ahmed AR, Matsumoto S et al : The concept of curative margin in surgery for bone and soft tissue sarcoma. Clin Orthop Relat Res 419 : 165-172, 2004
 
13) Matsumoto S (ed) : Modern Surgical Challenges for Musculoskeletal Sarcoma, Proceeding from 28th Annual Meeting of Surgical Treatment for Musculoskeletal Sarcoma, Vol 21, Tomizawa Printing, Tokyo, 2019
 
14) 蛭田啓之, 町並陸生, 岡本純佳 他 : 浸潤性発育を示す低悪性軟部肉腫の組織学的検討, 高悪性例との対比および切除縁との関連について. 日整会誌 81 : S722, 2007
Medical*Online
15) 松本誠一, 阿江啓介 : サルコーマの疫学と治療法の原則. 外科 80 : 301-307, 2018
 
16) 阿江啓介, 松本誠一 : 肉腫外科治療の最前線 : 切除縁-ユニークな切除縁評価法と, 根拠に基づく安全な手術計画. 医学のあゆみ 254 : 285-290, 2015
Medical*Online
17) 阿江啓介, 松本誠一 : 新しい切除縁評価とその概念. Bone Joint Nerve 7 : 459-468, 2017
Medical*Online

書評

最近チェックした商品履歴

Loading...